



(11)

EP 1 690 547 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
08.07.2009 Bulletin 2009/28

(51) Int Cl.:
A61K 39/00 ^(2006.01) **A61K 39/39** ^(2006.01)
A61P 25/28 ^(2006.01) **C07K 14/47** ^(2006.01)

(21) Application number: **06075704.4**

(22) Date of filing: **30.11.1998**

(54) **Prevention and treatment of amyloidogenic disease**

Vorbeugung und Behandlung von amyloidogener Krankheit

Prévention et traitement de maladie amyloïdogène

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **02.12.1997 US 67740 P**
07.04.1998 US 80970 P

(43) Date of publication of application:
16.08.2006 Bulletin 2006/33

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
98961833.5 / 1 033 996

(73) Proprietor: **Elan Pharma International Limited**
Athlone
Westmeath (IE)

(72) Inventor: **Schenk, Dale B.**
Burlingame, CA 94010-5941 (US)

(74) Representative: **Kirsch, Susan Edith et al**
Carpmaels & Ransford
43-45 Bloomsbury Square
London WC1A 2RA (GB)

(56) References cited:
EP-A- 0 683 234 WO-A-91/16819
WO-A-94/00153 WO-A-97/03192

- JOHNSON-WOOD K ET AL: "Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 94, no. 4, 18 February 1997 (1997-02-18), pages 1550-1555, XP002275435 ISSN: 0027-8424
- SAITO Y ET AL: "Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 92, no. 22, October 1995 (1995-10), pages 10227-10231, XP002090767 ISSN: 0027-8424
- WU ET AL: "Drug targeting of a peptide radiopharmaceutical through the primate blood - brain barrier in vivo with a monoclonal antibody to the human insulin receptor" JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 100, no. 7, October 1997 (1997-10), pages 1804-1812, XP002090766 ISSN: 0021-9738
- URMONEIT B ET AL: "CEREBROVASCULAR SMOOTH MUSCLE CELLS INTERNALIZE ALZHEIMER AMYLOID BETA PROTEIN VIA A LIPOPROTEIN PATHWAY: IMPLICATIONS FOR CEREBRAL AMYLOID ANGIOPATHY" LABORATORY INVESTIGATION, UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, BALTIMORE,, US, vol. 77, no. 2, August 1997 (1997-08), pages 157-166, XP002940016 ISSN: 0023-6837

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 690 547 B1

- LADU M J ET AL: "Isoform-specific binding of apolipoprotein E to beta-amyloid." THE JOURNAL OF BIOLOGICAL CHEMISTRY. 23 SEP 1994, vol. 269, no. 38, 23 September 1994 (1994-09-23), pages 23403-23406, XP002381631 ISSN: 0021-9258
- DU Y ET AL: "alpha2-Macroglobulin as a beta-amyloid peptide-binding plasma protein." JOURNAL OF NEUROCHEMISTRY. JUL 1997, vol. 69, no. 1, July 1997 (1997-07), pages 299-305, XP002381632 ISSN: 0022-3042
- SHINKAI Y ET AL: "Amyloid beta-proteins 1-40 and 1-42(43) in the soluble fraction of extra- and intracranial blood vessels." ANNALS OF NEUROLOGY. SEP 1995, vol. 38, no. 3, September 1995 (1995-09), pages 421-428, XP002381836 ISSN: 0364-5134
- TRAVIS: "A vaccine for Alzheimer's Disease?" SCIENCE, vol. 309, 2005, pages 731-734,
- SCIENCE, NEWS ONLINE, vol. 156, 10 July 1999 (1999-07-10), page 2,
- 8 May 2001 (2001-05-08), WASHINGTON POST * the whole document *
- ZUBRIGGEN ET AL.: J. MOL. NEUROSCIENCE, vol. 27, 2005, pages 157-166,
- BUTTINI ET AL.: J. NEUROSCIENCE, vol. 25, 2005, pages 9096-9101,
- MAIER ET AL.: J. NEUROSCIENCE, vol. 26, 2006, pages 4717-4728,
- WANG ET AL.: VACCINE, vol. 25, 2007, pages 3041-3052,
- DATABASE WWW.FREEP.COM [www.freep.com/news/health/alz23_20010723.h](http://www.freep.com/news/health/alz23_20010723.htm) tm 23 July 2001 (2001-07-23), SETH BORENSTEIN: "New Alzheimer's vaccine to be tested on people soon"

Description

TECHNICAL FIELD

5 **[0001]** The invention resides in the technical fields of immunology and medicine.

BACKGROUND

10 **[0002]** Alzheimer's disease (AD) is a progressive disease resulting in senile dementia. *See generally* Selkoe, TINS 16, 403-409 (1993); Hardy et al., WO 92/13069; Selkoe, J. Neuropathol. Exp. Neurol. 53, 438-447 (1994); Duff et al., Nature 373, 476-477 (1995); Games et al., Nature 373, 523 (1995). Broadly speaking the disease falls into two categories: late onset, which occurs in old age (65 + years) and early onset, which develops well before the senile period, i.e., between 35 and 60 years. In both types of disease, the pathology is the same but the abnormalities tend to be more severe and widespread in cases beginning at an earlier age. The disease is characterized by two types of lesions in the

15 brain, senile plaques and neurofibrillary tangles. Senile plaques are areas of disorganized neuropil up to 150 μ m across with extracellular amyloid deposits at the center visible by microscopic analysis of sections of brain tissue. Neurofibrillary tangles are intracellular deposits of tau protein consisting of two filaments twisted about each other in pairs.

[0003] The principal constituent of the plaques is a peptide termed A β or β -amyloid peptide. A β peptide is an internal fragment of 39-43 amino acids of a precursor protein termed amyloid precursor protein (APP). Several mutations within

20 the APP protein have been correlated with the presence of Alzheimer's disease. See, e.g., Goate et al., Nature 349, 704 (1991) (valine⁷¹⁷ to isoleucine); Chartier Harlan et al. Nature 353, 844 (1991) (valine⁷¹⁷ to glycine); Murrell et al., Science 254, 97 (1991) (valine⁷¹⁷ to phenylalanine); Mullan et al., Nature Genet. 1, 345 (1992) (a double mutation changing lysine⁵⁹⁵-methionine⁵⁹⁶ to asparagine⁵⁹⁵-leucine⁵⁹⁶). Such mutations are thought to cause Alzheimer's disease by increased or altered processing of APP to A β , particularly processing of APP to increased amounts of the long form of A β (i.e., A β 1-42 and A β 1-43). Mutations in other genes, such as the presenilin genes, PS1 and PS2, are thought

25 indirectly to affect processing of APP to generate increased amounts of long form A β (see Hardy, TINS 20, 154 (1997)). These observations indicate that A β , and particularly its long form, is a causative element in Alzheimer's disease.

[0004] McMichael, EP 526,511, proposes administration of homeopathic dosages (less than or equal to 10⁻² mg/day) of A β to patients with preestablished AD. In a typical human with about 5 liters of plasma, even the upper limit of this

30 dosage would be expected to generate a concentration of no more than 2 pg/ml. The normal concentration of A β in human plasma is typically in the range of 50-200 pg/ml (Seubert et al., Nature 359, 325-327 (1992)). Because EP 526,511's proposed dosage would barely alter the level of endogenous circulating A β and because EP 526,511 does not recommend use of an adjuvant, it seems implausible that any therapeutic benefit would result.

[0005] By contrast, the present invention is directed *inter alia* to treatment of Alzheimer's and other amyloidogenic

35 diseases by administration of A β or other immunogen to a patient under conditions that generate a beneficial immune response in the patient. The invention thus fulfills a longstanding need for therapeutic regimes for preventing or ameliorating the neuropathology of Alzheimer's disease.

SUMMARY OF THE CLAIMED INVENTION

40 **[0006]** The invention provides compositions and agents, as recited in the claims for preventing or treating a disease characterized by amyloid deposition in a patient. Such compositions and agents entail inducing an immune response against a peptide component of an amyloid deposit in the patient. Such induction is active by administration of an immunogen which is A β or an immunogenic fragment of A β . In some patients, the amyloid deposit is aggregated A β

45 peptide and the disease is Alzheimer's disease. The patient may be asymptomatic. The patient may be under 50 years of age. The patient may have inherited risk factors indicating susceptibility to Alzheimer's disease. Such risk factors include variant alleles in presenilin gene PS1 or PS2 and variant forms of APP. In other methods, the patient has no known risk factors for Alzheimer's disease.

[0007] For treatment of patients suffering from Alzheimer's disease, one treatment regime entails administering a dose

50 of A β peptide to the patient to induce the immune response. The A β peptide is administered with an adjuvant that enhances the immune response to the A β peptide. The adjuvant may be alum. The adjuvant may be MPL. The dose of A β peptide administered to the patient is typically at least 1 or 10 μ g. The dose may be at least 100 μ g.

[0008] The A β peptide may be A β 1-42. The A β peptide may be administered in aggregated form. The A β peptide is administered in dissociated form. The therapeutic agent may be an effective dose of a nucleic acid encoding A β or an

55 active fragment or derivative thereof. The nucleic acid encoding A β or fragment thereof is expressed in the patient to produce A β or the active fragment thereof, which induces the immune response. The nucleic acid may be administered through the skin, optionally via a patch.

[0009] The immune response may be directed to aggregated A β peptide without being directed to dissociated A β

peptide. For example, the immune response can comprise antibodies that bind to aggregated A β peptide without binding to dissociated A β peptide. The immune response may comprises T-cells that bind to A β complexed with MCH1 or MHCII on CD8 or CD4 cells.

[0010] The therapeutic agent is typically administered orally, intranasally, intradermally, subcutaneously, intramuscularly, topically or intravenously. The patient may be monitored followed administration to assess the immune response. If the monitoring indicates a reduction of the immune response over time, the patient can be given one or more further doses of the agent.

[0011] The invention provides pharmaceutical compositions comprising an agent effective to induce an immunogenic response against A β in a patient, and a pharmaceutically acceptable adjuvant. The agent is A β or an active fragment thereof. In some compositions, the adjuvant comprises alum. In some compositions, the adjuvant comprises an oil-in-water emulsion. In some compositions, the A β or active fragment is a component of a polylactide polyglycolide copolymer (PLPG) or other particle. The invention further provides compositions comprising A β or an active fragment linked to a conjugate molecule that promotes delivery of A β to the bloodstream of a patient and/or promotes an immune response against A β . For example, the conjugate can serve to promote an immune response against A β . In some compositions, the conjugate is cholera toxin. In some compositions, the conjugate is an immunoglobulin. In some compositions, the conjugate is attenuated diphtheria toxin CRM 197 (Gupta, Vaccine 15, 1341-3 (1997)).

[0012] The invention further provides for the use of A β , in the manufacture of a medicament for prevention or treatment of Alzheimer's disease.

[0013] In another aspect, the invention provides methods of assessing efficacy of an Alzheimer's treatment method in a patient. In these methods, a baseline amount of antibody specific for A β peptide is determined in a tissue sample from the patient before treatment with an agent. An amount of antibody specific for A β peptide in the tissue sample from the patient after treatment with the agent is compared to the baseline amount of A β peptide-specific antibody. An amount of A β peptide-specific antibody measured after the treatment that is significantly greater than the baseline amount of A β peptide-specific antibody indicates a positive treatment outcome.

[0014] In others methods of assessing efficacy of an Alzheimer's treatment method in a patient, a baseline amount of antibody specific for A β peptide in a tissue sample from a patient before treatment with an agent is determined. An amount of antibody specific for A β peptide in the tissue sample from the subject after treatment with the agent is compared to the baseline amount of A β peptide-specific antibody. A reduction or lack of significant difference between the amount of A β peptide-specific antibody measured after the treatment compared to the baseline amount of A β peptide-specific antibody indicates a negative treatment outcome.

[0015] In other methods of assessing efficacy of an Alzheimer's disease treatment method in a patient a control amount of antibody specific for A β peptide is determined in tissue samples from a control population. An amount of antibody specific for A β peptide in a tissue sample from the patient after administering an agent is compared to the control amount of A β peptide-specific antibody. An amount of A β peptide-specific antibody measured after the treatment that is significantly greater than the control amount of A β peptide-specific antibody indicates a positive treatment outcome.

[0016] In other methods of assessing efficacy of an Alzheimer's treatment method in a patient, a control amount of antibody specific for A β peptide in tissues samples from a control population is determined. An amount of antibody specific for A β peptide in a tissue sample from the patient after administering an agent is compared to the control amount of A β peptide-specific antibody. A lack of significant difference between the amount of A β peptide-specific antibody measured after beginning said treatment compared to the control amount of A β peptide-specific antibody indicates a negative treatment outcome.

[0017] Other methods of monitoring Alzheimer's disease or susceptibility thereto in a patient, comprise detecting an immune response against A β peptide in a sample from the patient. In some such methods, the patient is being administered an agent effective to treat or prevent Alzheimer's disease, and the level of the response determines the future treatment regime of the patient.

[0018] In other methods of assessing efficacy of an Alzheimer's treatment method in a patient a value for an amount of antibody specific for A β peptide in tissue sample from a patient who has been treated with an agent is determined. The value is compared with a control value determined from a population of patient experiencing amelioration of, or freedom from, symptoms of Alzheimer's disease due to treatment with the agent. A value in the patient at least equal to the control value indicates a positive response to treatment.

BRIEF DESCRIPTION OF THE FIGURES

[0019]

Fig. 1: Antibody titer after injection of transgenic mice with A β 1-42.

Fig. 2: Amyloid burden in the hippocampus. The percentage of the area of the hippocampal region occupied by amyloid plaques, defined by reactivity with the A β -specific mAb 3D6, was determined by computer-assisted quan-

titative image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group. The horizontal line for each grouping indicates the median value of the distribution.

Fig 3: Neuritic dystrophy in the hippocampus. The percentage of the area of the hippocampal region occupied by dystrophic neurites, defined by their reactivity with the human APP-specific mAb 8E5, was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown for the AN1792-treated group and the PBS-treated control group. The horizontal line for each grouping indicates the median value of the distribution.

Fig. 4: Astrocytosis in the retrosplenial cortex. The percentage of the area of the cortical region occupied by glial fibrillary acidic protein (GFAP)-positive astrocytes was determined by quantitative computer-assisted image analysis of immunoreacted brain sections. The values for individual mice are shown sorted by treatment group and median group values are indicated by horizontal lines.

Fig. 5: Geometric mean antibody titers to A β 1-42 following immunization with a range of eight doses of AN1792 containing 0.14, 0.4, 1.2, 3.7, 11, 33, 100, or 300 μ g.

Fig. 6: Kinetics of antibody response to AN1792 immunization. Titers are expressed as geometric means of values for the 6 animals in each group.

Fig. 7: Quantitative image analysis of the cortical amyloid burden in PBS- and AN1792-treated mice.

Fig. 8: Quantitative image analysis of the neuritic plaque burden in PBS- and AN1792-treated mice.

Fig. 9: Quantitative image analysis of the percent of the retrosplenial cortex occupied by astrocytosis in PBS- and AN1792-treated mice.

Fig. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (upper panel) or PBS-treated (lower panel).

Fig. 11: Total A β levels in the cortex. A scatterplot of individual A β profiles in mice immunized with A β or APP derivatives combined with Freund's adjuvant.

Fig. 12: Amyloid burden in the cortex was determined by quantitative image analysis of immunoreacted brain sections for mice immunized with the A β peptide conjugates A β 1-5, A β 1-12, and A β 13-28; the full length A β aggregates AN1792 (A β 1-42) and AN1528 (A β 1-40) and the PBS-treated control group.

Fig. 13: Geometric mean titers of A β -specific antibody for groups of mice immunized with A β or APP derivatives combined with Freund's adjuvant.

Fig. 14: Geometric mean titers of A β -specific antibody for groups of guinea pigs immunized with AN1792, or a palmitoylated derivative thereof, combined with various adjuvants.

Fig. 15: A β levels in the cortex of 12-month old PDAPP mice treated with AN1792 or AN1528 with different adjuvants.

DEFINITIONS

[0020] The term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 65 percent sequence identity, preferably at least 80 or 90 percent sequence identity, more preferably at least 95 percent sequence identity or more (e.g., 99 percent sequence identity or higher). Preferably, residue positions which are not identical differ by conservative amino acid substitutions.

[0021] For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

[0022] Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (*see generally* Ausubel *et al.*, *supra*). One example of algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul *et al.*, J. Mol. Biol. 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). Typically, default program parameters can be used to perform the sequence comparison, although customized parameters can also be used. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (*see* Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89, 10915 (1989)).

[0023] For purposes of classifying amino acids substitutions as conservative or nonconservative, amino acids are grouped as follows: Group I (hydrophobic sidechains): norleucine, met, ala, val, leu, ile; Group II (neutral hydrophilic

side chains): cys, ser, thr; Group III (acidic side chains): asp, glu; Group IV (basic side chains): asn, gln, his, lys, arg; Group V (residues influencing chain orientation): gly, pro; and Group VI (aromatic side chains): trp, tyr, phe. Conservative substitutions involve substitutions between amino acids in the same class. Non-conservative substitutions constitute exchanging a member of one of these classes for a member of another.

[0024] Therapeutic agents of the invention are typically substantially pure. This means that an agent is typically at least about 50% w/w (weight/weight) purity, as well as being substantially free from interfering proteins and contaminants. Sometimes the agents are at least about 80% w/w and, more preferably at least 90 or about 95% w/w purity. However, using conventional protein purification techniques, homogeneous peptides of at least 99% w/w can be obtained.

[0025] Specific binding between two entities means an affinity of at least 10^6 , 10^7 , 10^8 , 10^9 M⁻¹, or 10^{10} M⁻¹. Affinities greater than 10^8 M⁻¹ are preferred.

[0026] The term "antibody" is used to include intact antibodies and binding fragments thereof. Typically, fragments compete with the intact antibody from which they were derived for specific binding to an antigen. Optionally, antibodies or binding fragments thereof, can be chemically conjugated to, or expressed as, fusion proteins with other proteins.

[0027] APP⁶⁹⁵, APP⁷⁵¹, and APP⁷⁷⁰ refer, respectively, to the 695, 751, and 770 amino acid residue long polypeptides encoded by the human APP gene. See Kang et al., Nature 325, 773 (1987); Ponte et al., Nature 331, 525 (1988); and Kitaguchi et al., Nature 331, 530 (1988). Amino acids within the human amyloid precursor protein (APP) are assigned numbers according to the sequence of the APP770 isoform. Terms such as A β 39, A β 40, A β 41, A β 42 and A β 43 refer to an A β peptide containing amino acid residues 1-39, 1-40, 1-41, 1-42 and 1-43.

[0028] The term "epitope" or "antigenic determinant" refers to a site on an antigen to which B and/or T cells respond. B-cell epitopes can be formed both from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation. Methods of determining spatial conformation of epitopes include, for example, x-ray crystallography and 2-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, Glenn E. Morris, Ed. (1996). Antibodies that recognize the same epitope can be identified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen. T-cells recognize continuous epitopes of about nine amino acids for CD8 cells or about 13-15 amino acids for CD4 cells. T cells that recognize the epitope can be identified by *in vitro* assays that measure antigen-dependent proliferation, as determined by ³H-thymidine incorporation by primed T cells in response to an epitope (Burke et al., J. Inf. Dis. 170, 1110-19 (1994)), by antigen-dependent killing (cytotoxic T lymphocyte assay, Tigges et al., J. Immunol. 156, 3901-3910) or by cytokine secretion.

[0029] The term "immunological" or "immune" response is the development of a beneficial humoral (antibody mediated) and/or a cellular (mediated by antigen-specific T cells or their secretion products) response directed against an amyloid peptide in a recipient patient. Such a response can be an active response induced by administration of immunogen or a passive response induced by administration of antibody or primed T-cells. A cellular immune response is elicited by the presentation of polypeptide epitopes in association with Class I or Class II MHC molecules to activate antigen-specific CD4⁺ T helper cells and/or CD8⁺ cytotoxic T cells. The response may also involve activation of monocytes, macrophages, NK cells, basophils, dendritic cells, astrocytes, microglia cells, eosinophils or other components of innate immunity. The presence of a cell-mediated immunological response can be determined by proliferation assays (CD4⁺ T cells) or CTL (cytotoxic T lymphocyte) assays (see Burke, supra; Tigges, supra). The relative contributions of humoral and cellular responses to the protective or therapeutic effect of an immunogen can be distinguished by separately isolating IgG and T-cells from an immunized syngeneic animal and measuring protective or therapeutic effect in a second subject.

[0030] An "immunogenic agent" or "immunogen" is capable of inducing an immunological response against itself on administration to a patient, optionally in conjunction with an adjuvant.

[0031] The term "naked polynucleotide" refers to a polynucleotide not complexed with colloidal materials. Naked polynucleotides are sometimes cloned in a plasmid vector.

[0032] The term "adjuvant" refers to a compound that when administered in conjunction with an antigen augments the immune response to the antigen, but when administered alone does not generate an immune response to the antigen. Adjuvants can augment an immune response by several mechanisms including lymphocyte recruitment, stimulation of B and/or T cells, and stimulation of macrophages.

[0033] The term "patient" includes human and other mammalian subjects that receive either prophylactic or therapeutic treatment.

[0034] Disaggregated or monomeric A β means soluble, monomeric peptide units of A β . One method to prepare monomeric A β is to dissolve lyophilized peptide in neat DMSO with sonication.

[0035] The resulting solution is centrifuged to remove any nonsoluble particulates. Aggregated A β is a mixture of oligomers in which the monomeric units are held together by noncovalent bonds.

[0036] Compositions or methods "comprising" one or more recited elements may include other elements not specifically recited. For example, a composition that comprises A β peptide encompasses both an isolated A β peptide and A β peptide

as a component of a larger polypeptide sequence.

DETAILED DESCRIPTION

I. General

[0037] The invention provides pharmaceutical compositions and agents for prophylactic and therapeutic treatment of diseases characterized by accumulation of amyloid deposits. Amyloid deposits comprise a peptide aggregated to an insoluble mass. The nature of the peptide varies in different diseases but in most cases, the aggregate has a β -pleated sheet structure and stains with Congo Red dye. Diseases characterized by amyloid deposits include Alzheimer's disease (AD), both late and early onset. In both diseases, the amyloid deposit comprises a peptide termed A β , which accumulates in the brain of affected individuals. Examples of some other diseases characterized by amyloid deposits are SAA amyloidosis, hereditary Icelandic syndrome, multiple myeloma, and spongiform encephalopathies, including mad cow disease, Creutzfeldt Jakob disease, sheep scrapie, and mink spongiform encephalopathy (see Weissmann et al., Curr. Opin. Neurobiol. 7, 695-700 (1997); Smits et al., Veterinary Quarterly 19, 101-105 (1997); Nathanson et al., Am. J. Epidemiol. 145, 959-969 (1997)). The peptides forming the aggregates in these diseases are serum amyloid A, cystatin C, IgG kappa light chain respectively for the first three, and prion protein for the others.

II. Therapeutic Agents

1. Alzheimer's Disease

[0038] Therapeutic agents for use in the present invention induce an immune response against A β peptide. The agent is the A β peptide itself and fragments of A β peptide that induce and/or crossreact with antibodies to A β peptide, and antibodies or T-cells reactive with A β peptide. Induction of an immune response is active as when an immunogen is administered to induce antibodies or T-cells reactive with A β in a patient.

[0039] A β , also known as β -amyloid peptide, or A4 peptide (see US 4,666,829; Glenner & Wong, Biochem. Biophys. Res. Commun. 120, 1131 (1984)), is a peptide of 39-43 amino acids, which is the principal component of characteristic plaques of Alzheimer's disease. A β is generated by processing of a larger protein APP by two enzymes, termed β and γ secretases (see Hardy, TINS 20, 154 (1997)). Known mutations in APP associated with Alzheimer's disease occur proximate to the site of β or γ secretase, or within A β . For example, position 717 is proximate to the site of γ -secretase cleavage of APP in its processing to A β , and positions 670/671 are proximate to the site of β -secretase cleavage. It is believed that the mutations cause AD disease by interacting with the cleavage reactions by which A β is formed so as to increase the amount of the 42/43 amino acid form of A β generated.

[0040] A β has the unusual property that it can fix and activate both classical and alternate complement cascades. In particular, it binds to C1q and ultimately to C3bi. This association facilitates binding to macrophages leading to activation of B cells. In addition, C3bi breaks down further and then binds to CR2 on B cells in a T cell dependent manner leading to a 10,000 increase in activation of these cells. This mechanism causes A β to generate an immune response in excess of that of other antigens.

[0041] The therapeutic agent used in the claimed compositions and uses can be any of the naturally occurring forms of A β peptide, and particularly the human forms (i.e., A β 39, A β 40, A β 41, A β 42 or A β 43). The sequences of these peptides and their relationship to the APP precursor are illustrated by Fig. 1 of Hardy et al., TINS 20, 155-158 (1997). For example, A β 42 has the sequence:

H₂N-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-OH.

[0042] A β 41, A β 40 and A β 39 differ from A β 42 by the omission of Ala, Ala-Ile, and Ala-Ile-Val respectively from the C-terminal end. A β 43 differs from A β 42 by the presence of a threonine residue at the C-terminus. The therapeutic agent can also be an active fragment of a natural A β peptide that contains an epitope that induces a similar protective or therapeutic immune response on administration to a human. Immunogenic fragments typically have a sequence of at least 3, 5, 6, 10 or 20 contiguous amino acids from a natural peptide. Immunogenic fragments include A β 1-5, 1-6, 1-12, 13-28, 17-28, 25-25, 35-40 and 35-42. Fragments from the N-terminal half of A β are preferred in some compositions and uses. Fragments can be screened for prophylactic or therapeutic efficacy in transgenic animal models as described below.

[0043] A β and its fragments, can be synthesized by solid phase peptide synthesis or recombinant expression, or can be obtained from natural sources. Automatic peptide synthesizers are commercially available from numerous suppliers, such as Applied Biosystems, Foster City, California. Recombinant expression can be in bacteria, such as E. coli, yeast,

insect cells or mammalian cells. Procedures for recombinant expression are described by Sambrook et al., *Molecular Cloning: A Laboratory Manual* (C.S.H.P. Press, NY 2d ed., 1989). Some forms of A β peptide are also available commercially (e.g., American Peptides Company, Inc., Sunnyvale, CA and California Peptide Research, Inc. Napa, CA).

[0044] Therapeutic agents also include longer polypeptides that include, for example, an A β peptide or active fragment together with other amino acids. For example, A β peptide can be present as intact APP protein or a segment thereof, such as the C-100 fragment that begins at the N-terminus of A β and continues to the end of APP. Such polypeptides can be screened for prophylactic or therapeutic efficacy in animal models as described below. The A β peptide or active fragment can be administered in associated form (i.e., as an amyloid peptide) or in dissociated form. Therapeutic agents also include multimers of monomeric immunogenic agents.

[0045] In a further variation, an immunogenic peptide, such as A β , can be presented as a viral or bacterial vaccine. A nucleic acid encoding the immunogenic peptide is incorporated into a genome or episome of the virus or bacteria. Optionally, the nucleic acid is incorporated in such a manner that the immunogenic peptide is expressed as a secreted protein or as a fusion protein with an outersurface protein of a virus or a transmembrane protein of a bacteria so that the peptide is displayed. Viruses or bacteria used in such methods should be nonpathogenic or attenuated. Suitable viruses include adenovirus, HSV, vaccinia and fowl pox. Fusion of an immunogenic peptide to HBsAg of HBV is particularly suitable.

[0046] Random libraries of peptides or other compounds can also be screened for suitability. Combinatorial libraries can be produced for many types of compounds that can be synthesized in a step-by-step fashion. Such compounds include polypeptides, beta-turn mimetics, polysaccharides, phospholipids, hormones, prostaglandins, steroids, aromatic compounds, heterocyclic compounds, benzodiazepines, oligomeric N-substituted glycines and oligocarbamates. Large combinatorial libraries of the compounds can be constructed by the encoded synthetic libraries (ESL) method described in Affymax, WO 95/12608, Affymax, WO 93/06121, Columbia University, WO 94/08051, Pharmacopeia, WO 95/35503 and Scripps, WO 95/30642 (each of which is incorporated by reference for all purposes). Peptide libraries can also be generated by phage display methods. See, e.g., Devlin, WO 91/18980.

[0047] Combinatorial libraries and other compounds are initially screened for suitability by determining their capacity to bind to antibodies or lymphocytes (B or T) known to be specific for A β or other amyloidogenic peptides. For example, initial screens can be performed with any polyclonal sera or monoclonal antibody to A β or other amyloidogenic peptide. Compounds identified by such screens are then further analyzed for capacity to induce antibodies or reactive lymphocytes to A β or other amyloidogenic peptide. For example, multiple dilutions of sera can be tested on microtiter plates that have been precoated with A β peptide and a standard ELISA can be performed to test for reactive antibodies to A β . Compounds can then be tested for prophylactic and therapeutic efficacy in transgenic animals predisposed to an amyloidogenic disease, as described in the Examples. Such animals include, for example, mice bearing a 717 mutation of APP described by Games et al., *supra*, and mice bearing a Swedish mutation of APP such as described by McConlogue et al., US 5,612,486 and Hsiao et al., *Science* 274, 99 (1996); Staufenbiel et al., *Proc. Natl. Acad. Sci. USA* 94, 13287-13292 (1997); Sturchler-Pierrat et al., *Proc. Natl. Acad. Sci. USA* 94, 13287-13292 (1997); Borchelt et al., *Neuron* 19, 939-945 (1997)). The same screening approach can be used on other potential agents such as fragments of A β described above.

2. Other Diseases

[0048] The same or analogous principles determine production of therapeutic agents for treatment of other amyloidogenic diseases. In general, the agents noted above for use in treatment of Alzheimer's disease can also be used for treatment early onset Alzheimer's disease associated with Down's syndrome.

3. Carrier Proteins

[0049] Some agents for inducing an immune response contain the appropriate epitope for inducing an immune response against amyloid deposits but are too small to be immunogenic. In this situation, a peptide immunogen can be linked to a suitable carrier to help elicit an immune response. Suitable carriers include serum albumins, keyhole limpet hemocyanin, immunoglobulin molecules, thyroglobulin, ovalbumin, tetanus toxoid, or a toxoid from other pathogenic bacteria, such as diphtheria, *E. coli*, cholera, or *H. pylori*, or an attenuated toxin derivative. Other carriers for stimulating or enhancing an immune response include cytokines such as IL-1, IL-1 α and β peptides, IL-2, γ INF, IL-10, GM-CSF, and chemokines, such as MIP1 α and β and RANTES. Immunogenic agents can also be linked to peptides that enhance transport across tissues, as described in O'Mahony, WO 97/17613 and WO 97/17614.

[0050] Immunogenic agents can be linked to carriers by chemical crosslinking. Techniques for linking an immunogen to a carrier include the formation of disulfide linkages using N-succinimidyl-3-(2-pyridyl-thio) propionate (SPDP) and succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) (if the peptide lacks a sulfhydryl group, this can be provided by addition of a cysteine residue). These reagents create a disulfide linkage between themselves and peptide cysteine residues on one protein and an amide linkage through the ϵ -amino on a lysine, or other free amino group in

other amino acids. A variety of such disulfide/amide-forming agents are described by Immun. Rev. 62, 185 (1982). Other bifunctional coupling agents form a thioether rather than a disulfide linkage. Many of these thio-ether-forming agents are commercially available and include reactive esters of 6-maleimidocaproic acid, 2-bromoacetic acid, and 2-iodoacetic acid, 4-(N-maleimido-methyl)cyclohexane-1-carboxylic acid. The carboxyl groups can be activated by combining them with succinimide or 1-hydroxyl-2-nitro-4-sulfonic acid, sodium salt.

[0051] Immunogenic peptides can also be expressed as fusion proteins with carriers. The immunogenic peptide can be linked at the amino terminus, the carboxyl terminus, or internally to the carrier. Optionally, multiple repeats of the immunogenic peptide can be present in the fusion protein.

4. Nucleic Acid Encoding Immunogens

[0052] Immune responses against amyloid deposits can also be induced by administration of nucleic acids encoding A β peptide or other peptide immunogens. Such nucleic acids can be DNA or RNA. A nucleic acid segment encoding the immunogen is typically linked to regulatory elements, such as a promoter and enhancer, that allow expression of the DNA segment in the intended target cells of a patient. For expression in blood cells, as is desirable for induction of an immune response, promoter and enhancer elements from light or heavy chain immunoglobulin genes or the CMV major intermediate early promoter and enhancer are suitable to direct expression. The linked regulatory elements and coding sequences are often cloned into a vector.

[0053] A number of viral vector systems are available including retroviral systems (see, e.g., Lawrie and Tumin, Cur. Opin. Genet. Develop. 3, 102-109 (1993)); adenoviral vectors (see, e.g., Bett et al., J. Virol. 67, 5911 (1993)); adeno-associated virus vectors (see, e.g., Zhou et al., J. Exp. Med. 179, 1867 (1994)), viral vectors from the pox family including vaccinia virus and the avian pox viruses, viral vectors from the alpha virus genus such as those derived from Sindbis and Semliki Forest Viruses (see, e.g., Dubensky et al., J. Virol. 70, 508-519 (1996)), and papillomaviruses (Ohe et al., Human Gene Therapy 6, 325-333 (1995); Woo et al., WO 94/12629 and Xiao & Brandsma, Nucleic Acids. Res. 24, 2630-2622 (1996)).

[0054] DNA encoding an immunogen, or a vector containing the same, can be packaged into liposomes. Suitable lipids and related analogs are described by US 5,208,036, 5,264,618, 5,279,833 and 5,283,185. Vectors and DNA encoding an immunogen can also be adsorbed to or associated with particulate carriers, examples of which include polymethyl methacrylate polymers and polylactides and poly(lactide-co-glycolides), see, e.g., McGee et al., J. Micro Encap. (1996).

[0055] Gene therapy vectors or naked DNA can be delivered *in vivo* by administration to an individual patient, typically by systemic administration (e.g., intravenous, intraperitoneal, nasal, gastric, intradermal, intramuscular, subdermal, or intracranial infusion) or topical application (see e.g., US 5,399,346). DNA can also be administered using a gene gun. See Xiao & Brandsma, *supra*. The DNA encoding an immunogen is precipitated onto the surface of microscopic metal beads. The microprojectiles are accelerated with a shock wave or expanding helium gas, and penetrate tissues to a depth of several cell layers. For example, The AccelTM Gene Delivery Device manufactured by Agacetus, Inc. Middleton WI is suitable. Alternatively, naked DNA can pass through skin into the blood stream simply by spotting the DNA onto skin with chemical or mechanical irritation (see WO 95/05853).

[0056] In a further variation, vectors encoding immunogens can be delivered to cells *ex vivo*, such as cells explanted from an individual patient (e.g., lymphocytes, bone marrow aspirates, tissue biopsy) or universal donor hematopoietic stem cells, followed by reimplantation of the cells into a patient, usually after selection for cells which have incorporated the vector.

III. Patients Amenable to Treatment

[0057] Patients amenable to treatment include individuals at risk of disease but not showing symptoms, as well as patients presently showing symptoms. In the case of Alzheimer's disease, virtually anyone is at risk of suffering from Alzheimer's disease if he or she lives long enough. Therefore, the present methods can be administered prophylactically to the general population without any assessment of the risk of the subject patient. The present methods are especially useful for individuals who do have a known genetic risk of Alzheimer's disease. Such individuals include those having relatives who have experienced this disease, and those whose risk is determined by analysis of genetic or biochemical markers. Genetic markers of risk toward Alzheimer's disease include mutations in the APP gene, particularly mutations at position 717 and positions 670 and 671 referred to as the Hardy and Swedish mutations respectively (see Hardy, *TINS*, *supra*). Other markers of risk are mutations in the presenilin genes, PS1 and PS2, and ApoE4, family history of AD, hypercholesterolemia or atherosclerosis. Individuals presently suffering from Alzheimer's disease can be recognized from characteristic dementia, as well as the presence of risk factors described above. In addition, a number of diagnostic tests are available for identifying individuals who have AD. These include measurement of CSF tau and A β 42 levels. Elevated tau and decreased A β 42 levels signify the presence of AD. Individuals suffering from Alzheimer's disease can

also be diagnosed by MMSE or ADRDA criteria as discussed in the Examples section.

[0058] In asymptomatic patients, treatment can begin at any age (e.g., 10, 20, 30). Usually, however, it is not necessary to begin treatment until a patient reaches 40, 50, 60 or 70. Treatment typically entails multiple dosages over a period of time. Treatment can be monitored by assaying antibody, or activated T-cell or B-cell responses to the therapeutic agent (e.g., A β peptide) over time. If the response falls, a booster dosage is indicated. In the case of potential Down's syndrome patients, treatment can begin antenatally by administering therapeutic agent to the mother or shortly after birth.

IV. Treatment Regimes

[0059] In prophylactic applications, pharmaceutical compositions or medicants are administered to a patient susceptible to, or otherwise at risk of, a particular disease in an amount sufficient to eliminate or reduce the risk or delay the outset of the disease. In therapeutic applications, compositions or medicants are administered to a patient suspected of, or already suffering from such a disease in an amount sufficient to cure, or at least partially arrest, the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as a therapeutically- or pharmaceutically-effective dose. In both prophylactic and therapeutic regimes, agents are usually administered in several dosages until a sufficient immune response has been achieved. Typically, the immune response is monitored and repeated dosages are given if the immune response starts to fade.

[0060] Effective doses of the compositions of the present invention, for the treatment of the above described conditions vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic. Usually, the patient is a human, but in some diseases, such as mad cow disease, the patient can be a nonhuman mammal, such as a bovine. Treatment dosages need to be titrated to optimize safety and efficacy. The amount of immunogen depends on whether adjuvant is also administered, with higher dosages being required in the absence of adjuvant. The amount of an immunogen for administration sometimes varies from 1 μ g-500 μ g per patient and more usually from 5-500 μ g per injection for human administration. Occasionally, a higher dose of 1-2 mg per injection is used. Typically about 10, 20, 50 or 100 μ g is used for each human injection. The timing of injections can vary significantly from once a day, to once a year, to once a decade. On any given day that a dosage of immunogen is given, the dosage is greater than 1 μ g/patient and usually greater than 10 μ g/ patient if adjuvant is also administered, and greater than 10 μ g/patient and usually greater than 100 μ g/patient in the absence of adjuvant. A typical regimen consists of an immunization followed by booster injections at 6 weekly intervals. Another regimen consists of an immunization followed by booster injections 1, 2 and 12 months later. Another regimen entails an injection every two months for life. Alternatively, booster injections can be on an irregular basis as indicated by monitoring of immune response. Doses for nucleic acids encoding immunogens range from about 10 ng to 1 g, 100 ng to 100 mg, 1 μ g to 10 mg, or 30-300 μ g DNA per patient. Doses for infectious viral vectors vary from 10-10⁹, or more, virions per dose.

[0061] Agents for inducing an immune response can be administered by parenteral, topical, intravenous, oral, subcutaneous, intraperitoneal, intranasal or intramuscular means for prophylactic and/or therapeutic treatment. The most typical route of administration is subcutaneous although others can be equally effective. The next most common is intramuscular injection. This type of injection is most typically performed in the arm or leg muscles. Intravenous injections as well as intraperitoneal injections, intraarterial, intracranial, or intradermal injections are also effective in generating an immune response. In some methods, agents are injected directly into a particular tissue where deposits have accumulated.

[0062] Agents of the invention can optionally be administered in combination with other agents that are at least partly effective in treatment of amyloidogenic disease. In the case of Alzheimer's and Down's syndrome, in which amyloid deposits occur in the brain, agents of the invention can also be administered in conjunction with other agents that increase passage of the agents of the invention across the blood-brain barrier.

[0063] Immunogenic agents of the invention, such as peptides, are administered in combination with an adjuvant. A variety of adjuvants can be used in combination with a peptide, such as A β , to elicit an immune response. Preferred adjuvants augment the intrinsic response to an immunogen without causing conformational changes in the immunogen that affect the qualitative form of the response. Preferred adjuvants include alum, 3 De-O-acylated monophosphoryl lipid A (MPL) (see GB 2220211). QS21 is a triterpene glycoside or saponin isolated from the bark of the Quillaja Saponaria Molina tree found in South America (see Kensil et al., in Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman, Plenum Press, NY, 1995); US Patent No. 5,057,540). Other adjuvants are oil in water emulsions (such as squalene or peanut oil), optionally in combination with immune stimulants, such as monophosphoryl lipid A (see Stoute et al., N. Engl. J. Med. 336, 86-91 (1997)). Another adjuvant is CpG (Bioworld Today, Nov. 15, 1998). Alternatively, A β can be coupled to an adjuvant. For example, a lipopeptide version of A β can be prepared by coupling palmitic acid or other lipids directly to the N-terminus of A β as described for hepatitis B antigen vaccination (Livingston, J. Immunol. 159, 1383-1392 (1997)). However, such coupling should not substantially change the conformation of A β so as to affect the nature of the immune response thereto. Adjuvants can be administered as a component of a therapeutic composition

with an active agent or can be administered separately, before, concurrently with, or after administration of the therapeutic agent.

[0064] A preferred class of adjuvants is aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate. Such adjuvants can be used with or without other specific immunostimulating agents such as MPL or 3-DMP, QS21, polymeric or monomeric amino acids such as polyglutamic acid or polylysine. Another class of adjuvants is oil-in-water emulsion formulations. Such adjuvants can be used with or without other specific immunostimulating agents such as muramyl peptides (e.g., N-acetylmuramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), N-acetylglucosaminyl-N-acetylmuramyl-L-Al-D-isoglu-L-Ala-dipalmitoxy propylamide (DTP-DPP) theramide™), or other bacterial cell wall components. Oil-in-water emulsions include (a) MF59 (WO 90/14837), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton MA), (b) SAF, containing 10% Squalene, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP, either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) Ribi™ adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (Detox™). Another class of preferred adjuvants is saponin adjuvants, such as Stimulon™ (QS21, Aquila, Worcester, MA) or particles generated therefrom such as ISCOMs (immunostimulating complexes) and ISCOMATRIX. Other adjuvants include Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA). Other adjuvants include cytokines, such as interleukins (IL-1, IL-2, and IL-12), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF).

[0065] An adjuvant can be administered with an immunogen as a single composition, or can be administered before, concurrent with or after administration of the immunogen. Immunogen and adjuvant can be packaged and supplied in the same vial or can be packaged in separate vials and mixed before use. Immunogen and adjuvant are typically packaged with a label indicating the intended therapeutic application. If immunogen and adjuvant are packaged separately, the packaging typically includes instructions for mixing before use. The choice of an adjuvant and/or carrier depends on the stability of the vaccine containing the adjuvant, the route of administration, the dosing schedule, the efficacy of the adjuvant for the species being vaccinated, and, in humans, a pharmaceutically acceptable adjuvant is one that has been approved or is approvable for human administration by pertinent regulatory bodies. For example, Complete Freund's adjuvant is not suitable for human administration. Alum, MPL and QS21 are preferred. Optionally, two or more different adjuvants can be used simultaneously. Preferred combinations include alum with MPL, alum with QS21, MPL with QS21, and alum, QS21 and MPL together. Also, Incomplete Freund's adjuvant can be used (Chang et al., *Advanced Drug Delivery Reviews* 32, 173-186 (1998)), optionally in combination with any of alum, QS21, and MPL and all combinations thereof.

[0066] Agents of the invention are often administered as pharmaceutical compositions comprising an active therapeutic agent, *i.e.*, and a variety of other pharmaceutically acceptable components. See Remington's Pharmaceutical Science (15th ed., Mack Publishing Company, Easton, Pennsylvania, 1980). The preferred form depends on the intended mode of administration and therapeutic application. The compositions can also include, depending on the formulation desired, pharmaceutically-acceptable, non-toxic carriers or diluents, which are defined as vehicles commonly used to formulate pharmaceutical compositions for animal or human administration. The diluent is selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, physiological phosphate-buffered saline, Ringer's solutions, dextrose solution, and Hank's solution. In addition, the pharmaceutical composition or formulation may also include other carriers, adjuvants, or nontoxic, nontherapeutic, nonimmunogenic stabilizers and the like. However, some reagents suitable for administration to animals, such as Complete Freund's adjuvant are not typically included in compositions for human use.

[0067] Pharmaceutical compositions can also include large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids and copolymers (such as latex functionalized sepharose, agarose, cellulose, and the like), polymeric amino acids, amino acid copolymers, and lipid aggregates (such as oil droplets or liposomes). Additionally, these carriers can function as immunostimulating agents (*i.e.*, adjuvants).

[0068] For parenteral administration, agents of the invention can be administered as injectable dosages of a solution or suspension of the substance in a physiologically acceptable diluent with a pharmaceutical carrier which can be a sterile liquid such as water oils, saline, glycerol, or ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, surfactants, pH buffering substances and the like can be present in compositions. Other components of pharmaceutical compositions are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, and mineral oil. In general, glycols such as propylene glycol or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions.

[0069] Typically, compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared. The preparation also can

be emulsified or encapsulated in liposomes or micro particles such as polylactide, polyglycolide, or copolymer for enhanced adjuvant effect, as discussed above (see Langer, Science 249, 1527 (1990) and Hanes, Advanced Drug Delivery Reviews 28, 97-119 (1997)). The agents of this invention can be administered in the form of a depot injection or implant preparation which can be formulated in such a manner as to permit a sustained or pulsatile release of the active ingredient.

[0070] Additional formulations suitable for other modes of administration include oral, intranasal, and pulmonary formulations, suppositories, and transdermal applications.

[0071] For suppositories, binders and carriers include, for example, polyalkylene glycols or triglycerides; such suppositories can be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1%-2%. Oral formulations include excipients, such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, and magnesium carbonate. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10%-95% of active ingredient, preferably 25%-70%.

[0072] Topical application can result in transdermal or intradermal delivery. Topical administration can be facilitated by co-administration of the agent with cholera toxin or detoxified derivatives or subunits thereof or other similar bacterial toxins (See Glenn et al., Nature 391, 851 (1998)). Co-administration can be achieved by using the components as a mixture or as linked molecules obtained by chemical crosslinking or expression as a fusion protein.

[0073] Alternatively, transdermal delivery can be achieved using a skin path or using transferosomes (Paul et al., Eur. J. Immunol. 25, 3521-24 (1995); Cevc et al., Biochem. Biophys. Acta 1368, 201-15 (1998)).

V. Methods of Diagnosis

[0074] The invention provides methods of detecting an immune response against A β peptide in a patient suffering from or susceptible to Alzheimer's disease. The methods are particularly useful for monitoring a course of treatment being administered to a patient. The methods can be used to monitor both therapeutic treatment on symptomatic patients and prophylactic treatment on asymptomatic patients.

[0075] Some methods entail determining a baseline value of an immune response in a patient before administering a dosage of agent, and comparing this with a value for the immune response after treatment. A significant increase (i.e., greater than the typical margin of experimental error in repeat measurements of the same sample, expressed as one standard deviation from the mean of such measurements) in value of the immune response signals a positive treatment outcome (i.e., that administration of the agent has achieved or augmented an immune response). If the value for immune response does not change significantly, or decreases, a negative treatment outcome is indicated. In general, patients undergoing an initial course of treatment with an agent are expected to show an increase in immune response with successive dosages, which eventually reaches a plateau. Administration of agent is generally continued while the immune response is increasing. Attainment of the plateau is an indicator that the administered of treatment can be discontinued or reduced in dosage or frequency.

[0076] In other methods, a control value (i.e., a mean and standard deviation) of immune response is determined for a control population. Typically the individuals in the control population have not received prior treatment. Measured values of immune response in a patient after administering a therapeutic agent are then compared with the control value. A significant increase relative to the control value (e.g., greater than one standard deviation from the mean) signals a positive treatment outcome. A lack of significant increase or a decrease signals a negative treatment outcome. Administration of agent is generally continued while the immune response is increasing relative to the control value. As before, attainment of a plateau relative to control values is an indicator that the administration of treatment can be discontinued or reduced in dosage or frequency.

[0077] In other methods, a control value of immune response (e.g., a mean and standard deviation) is determined from a control population of individuals who have undergone treatment with a therapeutic agent and whose immune responses have plateaued in response to treatment. Measured values of immune response in a patient are compared with the control value. If the measured level in a patient is not significantly different (e.g., more than one standard deviation) from the control value, treatment can be discontinued. If the level in a patient is significantly below the control value, continued administration of agent is warranted. If the level in the patient persists below the control value, then a change in treatment regime, for example, use of a different adjuvant may be indicated.

[0078] In other methods, a patient who is not presently receiving treatment but has undergone a previous course of treatment is monitored for immune response to determine whether a resumption of treatment is required. The measured value of immune response in the patient can be compared with a value of immune response previously achieved in the patient after a previous course of treatment. A significant decrease relative to the previous measurement (i.e., greater than a typical margin of error in repeat measurements of the same sample) is an indication that treatment can be resumed. Alternatively, the value measured in patient can be compared with a control value (mean plus standard deviation) determined in population of patients after undergoing a course of treatment. Alternatively, the measured value in a patient can be compared with a control value in populations of prophylactically treated patients who remain free of symptoms

of disease, or populations of therapeutically treated patients who show amelioration of disease characteristics. In all of these cases, a significant decrease relative to the control level (i.e., more than a standard deviation) is an indicator that treatment should be resumed in a patient.

[0079] The tissue sample for analysis is typically blood, plasma, serum, mucus or cerebral spinal fluid from the patient. The sample is analyzed for indicia of an immune response to any form of A β peptide, typically A β ₄₂. The immune response can be determined from the presence of, e.g., antibodies or T-cells that specifically bind to A β peptide. ELISA methods of detecting antibodies specific to A β are described in the Examples section. Methods of detecting reactive T-cells have been described above (see Definitions).

EXAMPLES

I. Prophylactic Efficacy of A β Against AD

[0080] These examples describe administration of A β ₄₂ peptide to transgenic mice overexpressing APP with a mutation at position 717 (APP_{717V→F}) that predisposes them to develop Alzheimer's-like neuropathology. Production and characteristics of these mice (PDAPP mice) is described in Games et al., *Nature, supra*. These animals, in their heterozygote form, begin to deposit A β at six months of age forward. By fifteen months of age they exhibit levels of A β deposition equivalent to that seen in Alzheimer's disease. PDAPP mice were injected with aggregated A β ₄₂ (aggregated A β ₄₂) or phosphate buffered saline. Aggregated A β ₄₂ was chosen because of its ability to induce antibodies to multiple epitopes of A β .

A. Methods

1. Source of Mice

[0081] Thirty PDAPP heterogenic female mice were randomly divided into the following groups: 10 mice to be injected with aggregated A β ₄₂ (one died in transit), 5 mice to be injected with PBS/adjuvant or PBS, and 10 uninjected controls. Five mice were injected with serum amyloid protein (SAP).

2. Preparation of Immunogens

[0082] Preparation of aggregated A β ₄₂: two milligrams of A β ₄₂ (US Peptides Inc, lot K-42-12) was dissolved in 0.9 ml water and made up to 1 ml by adding 0.1 ml 10 x PBS. This was vortexed and allowed to incubate overnight 37° C, under which conditions the peptide aggregated. Any unused A β was stored as a dry lyophilized powder at -20° C until the next injection.

3. Preparation of Injections

[0083] 100 μ g of aggregated A β ₄₂ in PBS per mouse was emulsified 1:1 with Complete Freund's adjuvant (CFA) in a final volume of 400 μ l emulsion for the first immunization, followed by a boost of the same amount of immunogen in Incomplete Freund's adjuvant (IFA) at 2 weeks. Two additional doses in IFA were given at monthly intervals. The subsequent immunizations were done at monthly intervals in 500 μ l of PBS. Injections were delivered intraperitoneally (i.p.).

[0084] PBS injections followed the same schedule and mice were injected with a 1:1 mix of PBS/ Adjuvant at 400 μ l per mouse, or 500 μ l of PBS per mouse. SAP injections likewise followed the same schedule using a dose of 100 μ g per injection.

4. Titration of Mouse Bleeds, Tissue Preparation and Immunohistochemistry

[0085] The above methods are described *infra* in General Materials and Methods.

B. Results

[0086] PDAPP mice were injected with either aggregated A β ₄₂ (aggregated A β ₄₂), SAP peptides, or phosphate buffered saline. A group of PDAPP mice were also left as uninjected, positive controls. The titers of the mice to aggregated A β ₄₂ were monitored every other month from the fourth boost until the mice were one year of age. Mice were sacrificed at 13 months. At all time points examined, eight of the nine aggregated A β ₄₂ mice developed a high antibody titer, which remained high throughout the series of injections (titers greater than 1/10000). The ninth mouse had a low, but measurable

titer of approximately 1/1000 (Figure 1, Table 1). SAPP-injected mice had titers of 1:1,000 to 1:30,000 for this immunogen with only a single mice exceeding 1:10,000.

[0087] The PBS-treated mice were titrated against aggregated A β ₄₂ at six, ten and twelve months. At a 1/100 dilution the PBS mice when titrated against aggregated A β ₄₂ only exceeded 4 times background at one data point, otherwise, they were less than 4 times background at all time points (Table 1). The SAP-specific response was negligible at these time points with all titers less than 300.

[0088] Seven out of the nine mice in the aggregated A β 1-42 group had no detectable amyloid in their brains. In contrast, brain tissue from mice in the SAP and PBS groups contained numerous 3D6-positive amyloid deposits in the hippocampus, as well as in the frontal and cingulate cortices. The pattern of deposition was similar to that of untreated controls, with characteristic involvement of vulnerable subregions, such as the outer molecular layer of the hippocampal dentate gyrus. One mouse from the A β 1-42-injected group had a greatly reduced amyloid burden, confined to the hippocampus. An isolated plaque was identified in another A β 1-42-treated mouse.

[0089] Quantitative image analyses of the amyloid burden in the hippocampus verified the dramatic reduction achieved in the AN1792-treated animals (Fig. 2). The median values of the amyloid burden for the PBS group (2.22%), and for the untreated control group (2.65%) were significantly greater than for those immunized with AN1792 (0.00%, $p=0.0005$). In contrast, the median value for the group immunized with SAP peptides (SAPP) was 5.74%. Brain tissue from the untreated, control mice contained numerous A β amyloid deposits visualized with the A β -specific monoclonal antibody (mAb) 3D6 in the hippocampus, as well as in the retrosplenial cortex. A similar pattern of amyloid deposition was also seen in mice immunized with SAPP or PBS (Fig. 2). In addition, in these latter three groups there was a characteristic involvement of vulnerable subregions of the brain classically seen in AD, such as the outer molecular layer of the hippocampal dentate gyrus, in all three of these groups.

[0090] The brains that contained no A β deposits were also devoid of neuritic plaques that are typically visualized in PDAPP mice with the human APP antibody 8E5. All of brains from the remaining groups (SAP-injected, PBS and uninjected mice) had numerous neuritic plaques typical of untreated PDAPP mice. A small number of neuritic plaques were present in one mouse treated with AN1792, and a single cluster of dystrophic neurites was found in a second mouse treated with AN1792. Image analyses of the hippocampus, and shown in Fig. 3, demonstrated the virtual elimination of dystrophic neurites in AN1792-treated mice (median 0.00%) compared to the PBS recipients (median 0.28%, $p = 0.0005$).

[0091] Astrocytosis characteristic of plaque-associated inflammation was also absent in the brains of the A β 1-42 injected group. The brains from the mice in the other groups contained abundant and clustered GFAP-positive astrocytes typical of A β plaque-associated gliosis. A subset of the GFAP-reacted slides were counter-stained with Thioflavin S to localize the A β deposits. The GFAP-positive astrocytes were associated with A β plaques in the SAP, PBS and untreated controls. No such association was found in the plaque-negative A β 1-42 treated mice, while minimal plaque-associated gliosis was identified in one mouse treated with AN1792.

[0092] Image analyses, shown in Fig. 4 for the retrosplenial cortex, verified that the reduction in astrocytosis was significant with a median value of 1.56% for those treated with AN1792 versus median values greater than 6% for groups immunized with SAP peptides, PBS or untreated ($p=0.0017$).

[0093] Evidence from a subset of the A β 1-42- and PBS-injected mice indicated plaque-associated MHC II immunoreactivity was absent in the A β 1-42 injected mice, consistent with lack of an A β -related inflammatory response.

[0094] Sections of the mouse brains were also reacted with a mAb specific for MAC-1, a cell surface protein. MAC-1 (CD11b) is an integrin family member and exists as a heterodimer with CD18. The CD11b/CD18 complex is present on monocytes, macrophages, neutrophils and natural killer cells (Mak and Simard). The resident MAC-1-reactive cell type in the brain is likely to be microglia based on similar phenotypic morphology in MAC-1 immunoreacted sections. Plaque-associated MAC-1 labeling was lower in the brains of mice treated with AN1792 compared to the PBS control group, a finding consistent with the lack of an A β -induced inflammatory response.

C. Conclusion

[0095] The lack of A β plaques and reactive neuronal and gliotic changes in the brains of the A β 1-42-injected mice indicate that no or extremely little amyloid was deposited in their brains, and pathological consequences, such as gliosis and neuritic pathology, were absent. PDAPP mice treated with A β 1-42 show essentially the same lack of pathology as control nontransgenic mice. Therefore, A β 1-42 injections are highly effective in the prevention of deposition or clearance of human A β from brain tissue, and elimination of subsequent neuronal and inflammatory degenerative changes. Thus, administration of A β peptide has therapeutic benefit in prevention of AD.

II. Dose Response Study

[0096] Groups of five-week old, female Swiss Webster mice (N=6 per group) were immunized with 300, 100, 33, 11,

3.7, 1.2, 0.4, or 0.13 μ g of A β formulated in CFA/IFA administered intraperitoneally. Three doses were given at biweekly intervals followed by a fourth dose one month later. The first dose was emulsified with CFA and the remaining doses were emulsified with IFA. Animals were bled 4-7 days following each immunization starting after the second dose for measurement of antibody titers. Animals in a subset of three groups, those immunized with 11, 33, or 300 μ g of antigen, were additionally bled at approximately monthly intervals for four months following the fourth immunization to monitor the decay of the antibody response across a range of vaccine doses. These animals received a final fifth immunization at seven months after study initiation. They were sacrificed one week later to measure antibody responses to AN1792 and to perform toxicological analyses.

[0097] A declining dose response was observed from 300 to 3.7 μ g with no response at the two lowest doses. Mean antibody titers are about 1:1000 after 3 doses and about 1:10,000 after 4 doses of 11-300 μ g of antigen (see Fig. 5).

[0098] Antibody titers rose dramatically for all but the lowest dose group following the third immunization with increases in GMTs ranging from 5- to 25-fold. Low antibody responses were then detectable for even the 0.4 μ g recipients. The 1.2 and 3.7 μ g groups had comparable titers with GMTs of about 1000 and the highest four doses clustered together with GMTs of about 25,000, with the exception of the 33 μ g dose group with a lower GMT of 3000. Following the fourth immunization, the titer increase was more modest for most groups. There was a clear dose response across the lower antigen dose groups from 0.14 μ g to 11 μ g ranging from no detectable antibody for recipients of 0.14 μ g to a GMT of 36,000 for recipients of 11 μ g. Again, titers for the four highest dose groups of 11 to 300 μ g clustered together. Thus following two immunizations, the antibody titer was dependent on the antigen dose across the broad range from 0.4 to 300 μ g. By the third immunization, titers of the highest four doses were all comparable and they remained at a plateau after an additional immunization.

[0099] One month following the fourth immunization, titers were 2-to 3-fold higher in the 300 μ g group than those measured from blood drawn five days following the immunization (Fig. 6). This observation suggests that the peak anamnestic antibody response occurred later than 5 days post-immunization. A more modest (50%) increase was seen at this time in the 33 μ g group. In the 300 μ g dose group at two months following the last dose, GMTs declined steeply by about 70%. After another month, the decline was less steep at 45% (100 μ g) and about 14% for the 33 and 11 μ g doses. Thus, the rate of decline in circulating antibody titers following cessation of immunization appears to be biphasic with a steep decline the first month following peak response followed by a more modest rate of decrease thereafter.

[0100] The antibody titers and the kinetics of the response of these Swiss Webster mice are similar to those of young heterozygous PDAPP transgenic mice immunized in a parallel manner. Dosages effective to induce an immune response in humans are typically similar to dosages effective in mice.

III. Screen For Therapeutic Efficacy Against Established AD

[0101] This assay is designed to test immunogenic agents for activity in arresting or reversing neuropathological characteristics of AD in aged animals. Immunizations with 42 amino acid long A β (AN1792) were begun at a timepoint when amyloid plaques are already present in the brains of the PDAPP mice.

[0102] Over the timecourse used in this study, untreated PDAPP mice develop a number of neurodegenerative changes that resemble those found in AD (Games et al., *supra* and Johnson-Wood et al., Proc. Natl. Acad. Sci. USA 94, 1550-1555 (1997)). The deposition of A β into amyloid plaques is associated with a degenerative neuronal response consisting of aberrant axonal and dendritic elements, called dystrophic neurites. Amyloid deposits that are surrounded by and contain dystrophic neurites called neuritic plaques. In both AD and the PDAPP mouse, dystrophic neurites have a distinctive globular structure, are immunoreactive with a panel of antibodies recognizing APP and cytoskeletal components, and display complex subcellular degenerative changes at the ultrastructural level. These characteristics allow for disease-relevant, selective and reproducible measurements of neuritic plaque formation in the PDAPP brains. The dystrophic neuronal component of PDAPP neuritic plaques is easily visualized with an antibody specific for human APP (mAb 8E5), and is readily measurable by computer-assisted image analysis. Therefore, in addition to measuring the effects of AN1792 on amyloid plaque formation, we monitored the effects of this treatment on the development of neuritic dystrophy.

[0103] Astrocytes and microglia are non-neuronal cells that respond to and reflect the degree of neuronal injury. GFAP-positive astrocytes and MHC II-positive microglia are commonly observed in AD, and their activation increases with the severity of the disease. Therefore, we also monitored the development of reactive astrogliosis and microgliosis in the AN1792-treated mice.

A. Materials and Methods

[0104] Forty-eight, heterozygous female PDAPP mice, 11 to 11.5 months of age, obtained from Charles River, were randomly divided into two groups: 24 mice to be immunized with 100 μ g of AN1792 and 24 mice to be immunized with PBS, each combined with Freund's adjuvant. The AN1792 and PBS groups were again divided when they reached ~15 months of age. At 15 months of age approximately half of each group of the AN1792- and PBS-treated animals were

ethanized (n=10 and 9, respectively), the remainder continued to receive immunizations until termination at ~18 months (n=9 and 12, respectively). A total of 8 animals (5 AN1792, 3 PBS) died during the study. In addition to the immunized animals, one-year old (n=10), 15-month old (n=10) and 18-month old (n=10) untreated PDAPP mice were included for comparison in the ELISAs to measure $\text{A}\beta$ and APP levels in the brain; the one-year old animals were also included in the immunohistochemical analyses.

[0105] Methodology was as in Example 1 unless otherwise indicated. US Peptides lot 12 and California Peptides lot ME0339 of AN1792 were used to prepare the antigen for the six immunizations administered prior to the 15-month timepoint. California Peptides lots ME0339 and ME0439 were used for the three additional immunizations administered between 15 and 18 months.

[0106] For immunizations, 100 μg of AN1792 in 200 μl PBS or PBS alone was emulsified 1:1 (vol:vol) with Complete Freund's adjuvant (CFA) or Incomplete Freund's adjuvant (IFA) or PBS in a final volume of 400 μl . The first immunization was delivered with CFA as adjuvant, the next four doses were given with IFA and the final four doses with PBS alone without added adjuvant. A total of nine immunizations were given over the seven-month period on a two-week schedule for the first three doses followed by a four-week interval for the remaining injections. The four-month treatment group, euthanized at 15 months of age, received only the first 6 immunizations.

B. Results

1. Effects of AN1792 Treatment on Amyloid Burden

[0107] The results of AN1792 treatment on cortical amyloid burden determined by quantitative image analysis are shown in Fig. 7. The median value of cortical amyloid burden was 0.28% in a group of untreated 12-month old PDAPP mice, a value representative of the plaque load in mice at the study's initiation. At 18 months, the amyloid burden increased over 17-fold to 4.87% in PBS-treated mice, while AN1792-treated mice had a greatly reduced amyloid burden of only 0.01%, notably less than the 12-month untreated and both the 15- and 18-month PBS-treated groups. The amyloid burden was significantly reduced in the AN1792 recipients at both 15 (96% reduction; $p=0.003$) and 18 (>99% reduction; $p=0.0002$) months.

[0108] Typically, cortical amyloid deposition in PDAPP mice initiates in the frontal and retrosplenial cortices (RSC) and progresses in a ventral-lateral direction to involve the temporal and entorhinal cortices (EC). Little or no amyloid was found in the EC of 12 month-old mice, the approximate age at which AN1792 was first administered. After 4 months of AN1792 treatment, amyloid deposition was greatly diminished in the RSC, and the progressive involvement of the EC was entirely eliminated by AN1792 treatment. The latter observation showed that AN1792 completely halted the progression of amyloid that would normally invade the temporal and ventral cortices, as well as arrested or possibly reversed deposition in the RSC.

[0109] The profound effects of AN1792 treatment on developing cortical amyloid burden in the PDAPP mice are further demonstrated by the 18-month group, which had been treated for seven months. A near complete absence of cortical amyloid was found in the AN1792-treated mouse, with a total lack of diffuse plaques, as well as a reduction in compacted deposits.

2. AN1792 Treatment-associated Cellular and Morphological Changes

[0110] A population of $\text{A}\beta$ -positive cells was found in brain regions that typically contain amyloid deposits. Remarkably, in several brains from AN1792 recipients, very few or no extracellular cortical amyloid plaques were found. Most of the $\text{A}\beta$ immunoreactivity appeared to be contained within cells with large lobular or clumped soma. Phenotypically, these cells resembled activated microglia or monocytes. They were immunoreactive with antibodies recognizing ligands expressed by activated monocytes and microglia (MHC II and CD11b) and were occasionally associated with the wall or lumen of blood vessels. Comparison of near-adjacent sections labeled with $\text{A}\beta$ and MHC II-specific antibodies revealed that similar patterns of these cells were recognized by both classes of antibodies. Detailed examination of the AN1792-treated brains revealed that the MHC II-positive cells were restricted to the vicinity of the limited amyloid remaining in these animals. Under the fixation conditions employed, the cells were not immunoreactive with antibodies that recognize T cell (CD3, CD3e) or B cell (CD45RA, CD45RB) ligands or leukocyte common antigen (CD45), but were reactive with an antibody recognizing leukosialin (CD43) which cross-reacts with monocytes. No such cells were found in any of the PBS-treated mice.

[0111] PDAPP mice invariably develop heavy amyloid deposition in the outer molecular layer of the hippocampal dentate gyrus. The deposition forms a distinct streak within the perforant pathway, a subregion that classically contains amyloid plaques in AD. The characteristic appearance of these deposits in PBS-treated mice resembled that previously characterized in untreated PDAPP mice. The amyloid deposition consisted of both diffuse and compacted plaques in a continuous band. In contrast, in a number of brains from AN1792-treated mice this pattern was drastically altered. The

hippocampal amyloid deposition no longer contained diffuse amyloid, and the banded pattern was completely disrupted. Instead, a number of unusual punctate structures were present that are reactive with anti-A β antibodies, several of which appeared to be amyloid-containing cells.

[0112] MHC II-positive cells were frequently observed in the vicinity of extracellular amyloid in AN1792-treated animals. The pattern of association of A β -positive cells with amyloid was very similar in several brains from AN1792-treated mice. The distribution of these monocytic cells was restricted to the proximity of the deposited amyloid and was entirely absent from other brain regions devoid of A β plaques.

[0113] Quantitative image analysis of MHC II and MAC I-labeled sections revealed a trend towards increased immunoreactivity in the RSC and hippocampus of AN1792-treated mice compared to the PBS group which reached significance with the measure of MAC 1 reactivity in hippocampus.

[0114] These results are indicative of active, cell-mediated removal of amyloid in plaque-bearing brain regions.

3. AN1792 Effects on A β Levels: ELISA Determinations

(a) Cortical Levels

[0115] In untreated PDAPP mice, the median level of total A β in the cortex at 12 months was 1,600 ng/g, which increased to 8,700 ng/g by 15 months (Table 2). At 18 months the value was 22,000 ng/g, an increase of over 10-fold during the time course of the experiment. PBS-treated animals had 8,600 ng/g total A β at 15 months which increased to 19,000 ng/g at 18 months. In contrast, AN1792-treated animals had 81% less total A β at 15 months (1,600 ng/g) than the PBS-immunized group. Significantly less ($p=0.0001$) total A β (5,200 ng/g) was found at 18 months when the AN1792 and PBS groups were compared (Table 2), representing a 72% reduction in the A β that would otherwise be present. Similar results were obtained when cortical levels of A β 42 were compared, namely that the AN1792-treated group contained much less A β 42, but in this case the differences between the AN1792 and PBS groups were significant at both 15 months ($p=0.04$) and 18 months ($p=0.0001$, Table 2).

Table 2: Median A β Levels (ng/g) in Cortex

Age	UNTREATED			PBS			AN1792		
	Total A β	A β 42	(n)	Total A β	A β 42	(n)	Total	A β 42	(n)
12	1,600	1,300	(10)						
15	8,700	8,300	(10)	8,600	7,200	(9)	1,600	1,300*	(10)
18	22,200	18,500	(10)	19,000	15,900	(12)	5,200**	4,000**	(9)
* $p=0.0412$									
** $p=0.0001$									

(b) Hippocampal Levels

[0116] In untreated PDAPP mice, median hippocampal levels of total A β at twelve months of age were 15,000 ng/g which increased to 51,000 ng/g at 15 months and further to 81,000 ng/g at 18 months (Table 3). Similarly, PBS immunized mice showed values of 40,000 ng/g and 65,000 ng/g at 15 months and 18 months, respectively. AN1792 immunized animals exhibited less total A β , specifically 25,000 ng/g and 51,000 ng/g at the respective 15-month and 18-month timepoints. The 18-month AN1792-treated group value was significantly lower than that of the PBS treated group ($p=0.0105$; Table 3). Measurement of A β 42 gave the same pattern of results, namely that levels in the AN1792-treated group were significantly lower than in the PBS group (39,000 ng/g vs. 57,000 ng/g, respectively; $p=0.0022$) at the 18-month evaluation (Table 3).

Table 3: Median A β Levels (ng/g) in Hippocampus

Age	UNTREATED			PBS			AN1792		
	Total A β	A β 42	(n)	Total A β	A β 42	(n)	Total	A β 42	(n)
12	15,500	11,100	(10)						
15	51,500	44,400	(10)	40,100	35,700	(9)	24,500	22,100	(10)

(continued)

UNTREATED				PBS			AN1792		
Age	Total A β	A β 42	(n)	Total A β	A β 42	(n)	Total	A β 42	(n)
18	80,800	64,200	(10)	65,400	57,100	(12)	50,900*	38,900**	(9)
* p = 0.0105 ** p = 0.0022									

(c) Cerebellar Levels

[0117] In 12-month untreated PDAPP mice, the median cerebellar level of total A β was 15 ng/g (Table 4). At 15 months, this median increased to 28 ng/g and by 18 months had risen to 35 ng/g. PBS-treated animals displayed median total A β values of 21 ng/g at 15 months and 43 ng/g at 18 months. AN1792-treated animals were found to have 22 ng/g total A β at 15 months and significantly less ($p=0.002$) total A β at 18 months (25 ng/g) than the corresponding PBS group (Table 4).

Table 4: Median A β Levels (ng/g) in Cerebellum

UNTREATED			PBS		AN1792	
Age (months)	Total A β	(n)	Total A β	(n)	Total A β	(n)
12	15.6	(10)				
15	27.7	(10)	20.8	(9)	21.7	(10)
18	35.0	(10)	43.1	(12)	24.8*	(9)
* p = 0.0018						

4. Effects of AN1792 Treatment on APP Levels

[0118] APP- α and the full-length APP molecule both contain all or part of the A β sequence and thus could be potentially impacted by the generation of an AN1792-directed immune response. In studies to date, a slight increase in APP levels has been noted as neuropathology increases in the PDAPP mouse. In the cortex, levels of either APP- α /FL (full length) or APP- α were essentially unchanged by treatment with the exception that APP- α was reduced by 19% at the 18-month timepoint in the AN1792-treated vs. the PBS-treated group. The 18-month AN1792-treated APP values were not significantly different from values of the 12-month and 15-month untreated and 15-month PBS groups. In all cases the APP values remained within the ranges that are normally found in PDAPP mice.

5. Effects of AN1792 Treatment on Neurodegenerative and Gliotic Pathology

[0119] Neuritic plaque burden was significantly reduced in the frontal cortex of AN1792-treated mice compared to the PBS group at both 15 (84%; $p=0.03$) and 18 (55%; $p=0.01$) months of age (Fig. 8). The median value of the neuritic plaque burden increased from 0.32% to 0.49% in the PBS group between 15 and 18 months of age. This contrasted with the greatly reduced development of neuritic plaques in the AN1792 group, with median neuritic plaque burden values of 0.05% and 0.22%, in the 15 and 18 month groups, respectively.

[0120] Immunizations with AN1792 seemed well tolerated and reactive astrogliosis was also significantly reduced in the RSC of AN1792-treated mice when compared to the PBS group at both 15 (56%; $p=0.011$) and 18 (39%; $p=0.028$) months of age (Fig. 9). Median values of the percent of astrogliosis in the PBS group increased between 15 and 18 months from 4.26% to 5.21%. AN1792-treatment suppressed the development of astrogliosis at both time points to 1.89% and 3.2%, respectively. This suggests the neuropil was not being damaged by the clearance process.

6. Antibody Responses

[0121] As described above, eleven-month old, heterozygous PDAPP mice ($N=24$) received a series of 5 immunizations of 100 μ g of AN1792 emulsified with Freund's adjuvant and administered intraperitoneally at weeks 0, 2, 4, 8, and 12, and a sixth immunization with PBS alone (no Freund's adjuvant) at week 16. As a negative control, a parallel set of 24 age-matched transgenic mice received immunizations of PBS emulsified with the same adjuvants and delivered on the same schedule. Animals were bled within three to seven days following each immunization starting after the second

dose. Antibody responses to AN1792 were measured by ELISA. Geometric mean titers (GMT) for the animals that were immunized with AN1792 were approximately 1,900, 7,600, and 45,000 following the second, third and last (sixth) doses respectively. No A β -specific antibody was measured in control animals following the sixth immunization.

[0122] Approximately one-half of the animals were treated for an additional three months, receiving immunizations at about 20, 24 and 27 weeks. Each of these doses was delivered in PBS vehicle alone without Freund's adjuvant. Mean antibody titers remained unchanged over this time period. In fact, antibody titers appeared to remain stable from the fourth to the eighth bleed corresponding to a period covering the fifth to the ninth injections.

[0123] To determine if the A β -specific antibodies elicited by immunization that were detected in the sera of AN1792-treated mice were also associated with deposited brain amyloid, a subset of sections from the AN1792- and PBS-treated mice were reacted with an antibody specific for mouse IgG. In contrast to the PBS group, A β plaques in AN1792-treated brains were coated with endogenous IgG. This difference between the two groups was seen in both 15- and 18-month groups. Particularly striking was the lack of labeling in the PBS group, despite the presence of a heavy amyloid burden in these mice. These results show that immunization with a synthetic A β protein generates antibodies that recognize and bind *in vivo* to the A β in amyloid plaques.

7. Cellular-Mediated Immune Responses

[0124] Spleens were removed from nine AN1792-immunized and 12 PBS-immunized 18-month old PDAPP mice 7 days after the ninth immunization. Splenocytes were isolated and cultured for 72 h in the presence of A β 40, A β 42, or A β 40-1 (reverse order protein). The mitogen Con A served as a positive control. Optimum responses were obtained with >1.7 μ M protein. Cells from all nine AN1792-treated animals proliferated in response to either A β 1-40 or A β 1-42 protein, with equal levels of incorporation for both proteins (Fig. 10, Upper Panel). There was no response to the A β 40-1 reverse protein. Cells from control animals did not respond to any of the A β proteins (Fig. 10, Lower Panel).

C. Conclusion

[0125] The results of this study show that AN1792 immunization of PDAPP mice possessing existing amyloid deposits slows and prevents progressive amyloid deposition and retard consequential neuropathological changes in the aged PDAPP mouse brain. Immunizations with AN1792 essentially halted amyloid developing in structures that would normally succumb to amyloidosis. Thus, administration of A β peptide has therapeutic benefit in the treatment of AD.

IV. Screen of A β Fragments

[0126] 100 PDAPP mice age 9-11 months are immunized with 9 different regions of APP and A β to determine which epitopes convey the response. The 9 different immunogens and one control are injected i.p. as described above. The immunogens include four human A β peptide conjugates 1-12, 13-28, 32-42, 1-5, all coupled to sheep anti-mouse IgG via a cystine link; an APP polypeptide aa 592-695, aggregated human A β 1-40, and aggregated human A β 25-35, and aggregated rodent A β 42. Aggregated A β 42 and PBS are used as controls. Ten mice are used per treatment group. Titers are monitored as above and mice are euthanized at the end of 4 months of injections. Histochemistry, A β levels, and toxicology are determined post mortem.

A. Materials and Methods

1. Preparation of Immunogens

[0127] Preparation of coupled A β peptides: four human A β peptide conjugates (amino acid residues 1-5, 1-12, 13-28, and 33-42, each conjugated to sheep anti-mouse IgG) were prepared by coupling through an artificial cysteine added to the A β peptide using the crosslinking reagent sulfo-EMCS. The A β peptide derivatives were synthesized with the following final amino acid sequences. In each case, the location of the inserted cysteine residue is indicated by underlining. The A β 13-28 peptide derivative also had two glycine residues added prior to the carboxyl terminal cysteine as indicated.

A β 1-12 peptide	NH ₂ -DAEFRHDSGYEVC <u>COOH</u>
A β 1-5 peptide	NH ₂ -DAEFR <u>C</u> COOH
A β 33-42 peptide	NH ₂ - <u>C</u> -amino-heptanoic acid-GLMVGGVVIA COOH
A β 13-28 peptide	Ac-NH-HHQKLVFFAEDVGSNKG <u>GC</u> -COOH

[0128] To prepare for the coupling reaction, ten mg of sheep anti-mouse IgG (Jackson ImmunoResearch Laboratories) was dialyzed overnight against 10 mM sodium borate buffer, pH 8.5. The dialyzed antibody was then concentrated to

a volume of 2 mL using an Amicon Centriprep tube. Ten mg sulfo-EMCS [N (ϵ -maleimidocaproyloxy) succinimide] (Molecular Sciences Co.) was dissolved in one mL deionized water. A 40-fold molar excess of sulfo-EMCS was added dropwise with stirring to the sheep anti-mouse IgG and then the solution was stirred for an additional ten min. The activated sheep anti-mouse IgG was purified and buffer exchanged by passage over a 10 mL gel filtration column (Pierce Presto Column, obtained from Pierce Chemicals) equilibrated with 0.1 M NaPO₄, 5 mM EDTA, pH 6.5. Antibody containing fractions, identified by absorbance at 280 nm, were pooled and diluted to a concentration of approximately 1 mg/mL, using 1.4 mg per OD as the extinction coefficient. A 40-fold molar excess of A β peptide was dissolved in 20 mL of 10 mM NaPO₄, pH 8.0, with the exception of the A β 33-42 peptide for which 10 mg was first dissolved in 0.5 mL of DMSO and then diluted to 20 mL with the 10 mM NaPO₄ buffer. The peptide solutions were each added to 10 mL of activated sheep anti-mouse IgG and rocked at room temperature for 4 hr. The resulting conjugates were concentrated to a final volume of less than 10 mL using an Amicon Centriprep tube and then dialyzed against PBS to buffer exchange the buffer and remove free peptide. The conjugates were passed through 0.22 μ -pore size filters for sterilization and then aliquoted into fractions of 1 mg and stored frozen at -20°C. The concentrations of the conjugates were determined using the BCA protein assay (Pierce Chemicals) with horse IgG for the standard curve. Conjugation was documented by the molecular weight increase of the conjugated peptides relative to that of the activated sheep anti-mouse IgG. The A β 1-5 sheep anti-mouse conjugate was a pool of two conjugations, the rest were from a single preparation.

2. Preparation of aggregated A β peptides

[0129] Human 1-40 (AN1528; California Peptides Inc., Lot ME0541), human 1-42 (AN1792; California Peptides Inc., Lots ME0339 and ME0439), human 25-35, and rodent 1-42 (California Peptides Inc., Lot ME0218) peptides were freshly solubilized for the preparation of each set of injections from lyophilized powders that had been stored desiccated at -20°C. For this purpose, two mg of peptide were added to 0.9 ml of deionized water and the mixture was vortexed to generate a relatively uniform solution or suspension. Of the four, AN1528 was the only peptide soluble at this step. A 100 μ l aliquot of 10X PBS (1X PBS: 0.15 M NaCl, 0.01 M sodium phosphate, pH 7.5) was then added at which point AN1528 began to precipitate. The suspension was vortexed again and incubated overnight at 37°C for use the next day.

[0130] Preparation of the pBx6 protein: An expression plasmid encoding pBx6, a fusion protein consisting of the 100-amino acid bacteriophage MS-2 polymerase N-terminal leader sequence followed by amino acids 592-695 of APP (β APP) was constructed as described by Oltersdorf et al., J. Biol. Chem. 265, 4492-4497 (1990). The plasmid was transfected into *E. coli* and the protein was expressed after induction of the promoter. The bacteria were lysed in 8M urea and pBx6 was partially purified by preparative SDS PAGE. Fractions containing pBx6 were identified by Western blot using a rabbit anti-pBx6 polyclonal antibody, pooled, concentrated using an Amicon Centriprep tube and dialysed against PBS. The purity of the preparation, estimated by Coomassie Blue stained SDS PAGE, was approximately 5 to 10%.

B. Results and Discussion

1. Study Design

[0131] One hundred male and female, nine- to eleven-month old heterozygous PDAPP transgenic mice were obtained from Charles River Laboratory and Taconic Laboratory. The mice were sorted into ten groups to be immunized with different regions of A β or APP combined with Freund's adjuvant. Animals were distributed to match the gender, age, parentage and source of the animals within the groups as closely as possible. The immunogens included four A β peptides derived from the human sequence, 1-5, 1-12, 13-28, and 33-42, each conjugated to sheep anti-mouse IgG; four aggregated A β peptides, human 1-40 (AN1528), human 1-42 (AN1792), human 25-35, and rodent 1-42; and a fusion polypeptide, designated as pBx6, containing APP amino acid residues 592-695. A tenth group was immunized with PBS combined with adjuvant as a control.

[0132] For each immunization, 100 μ g of each A β peptide in 200 μ l PBS or 200 μ g of the APP derivative pBx6 in the same volume of PBS or PBS alone was emulsified 1:1 (vol:vol) with Complete Freund's adjuvant (CFA) in a final volume of 400 μ l for the first immunization, followed by a boost of the same amount of immunogen in Incomplete Freund's adjuvant (IFA) for the subsequent four doses and with PBS for the final dose. Immunizations were delivered intraperitoneally on a biweekly schedule for the first three doses, then on a monthly schedule thereafter. Animals were bled four to seven days following each immunization starting after the second dose for the measurement of antibody titers. Animals were euthanized approximately one week after the final dose.

2. A β and APP Levels in the Brain

[0133] Following about four months of immunization with the various A β peptides or the APP derivative, brains were

removed from saline-perfused animals. One hemisphere was prepared for immunohistochemical analysis and the second was used for the quantitation of A β and APP levels. To measure the concentrations of various forms of beta amyloid peptide and amyloid precursor protein, the hemisphere was dissected and homogenates of the hippocampal, cortical, and cerebellar regions were prepared in 5 M guanidine. These were diluted and the level of amyloid or APP was quantitated by comparison to a series of dilutions of standards of A β peptide or APP of known concentrations in an ELISA format.

[0134] The median concentration of total A β for the control group immunized with PBS was 5.8-fold higher in the hippocampus than in the cortex (median of 24,318 ng/g hippocampal tissue compared to 4,221 ng/g for the cortex). The median level in the cerebellum of the control group (23.4 ng/g tissue) was about 1,000-fold lower than in the hippocampus. These levels are similar to those that we have previously reported for heterozygous PDAPP transgenic mice of this age (Johnson-Woods et al., 1997, supra).

[0135] For the cortex, a subset of treatment groups had median total A β and A β 1-42 levels which differed significantly from those of the control group ($p < 0.05$), those animals receiving AN1792, rodent A β 1-42 or the A β 1-5 peptide conjugate as shown in Fig. 11. The median levels of total A β were reduced by 75%, 79% and 61%, respectively, compared to the control for these treatment groups. There were no discernable correlations between A β -specific antibody titers and A β levels in the cortical region of the brain for any of the groups.

[0136] In the hippocampus, the median reduction of total A β associated with AN1792 treatment (46%, $p = 0.0543$) was not as great as that observed in the cortex (75%, $p = 0.0021$). However, the magnitude of the reduction was far greater in the hippocampus than in the cortex, a net reduction of 11,186 ng/g tissue in the hippocampus versus 3,171 ng/g tissue in the cortex. For groups of animals receiving rodent A β 1-42 or A β 1-5, the median total A β levels were reduced by 36% and 26%, respectively. However, given the small group sizes and the high variability of the amyloid peptide levels from animal to animal within both groups, these reductions were not significant. When the levels of A β 1-42 were measured in the hippocampus, none of the treatment-induced reductions reached significance. Thus, due to the smaller A β burden in the cortex, changes in this region are a more sensitive indicator of treatment effects. The changes in A β levels measured by ELISA in the cortex are similar, but not identical, to the results from the immunohistochemical analysis (see below).

[0137] Total A β was also measured in the cerebellum, a region typically unaffected in the AD pathology. None of the median A β concentrations of any of the groups immunized with the various A β peptides or the APP derivative differed from that of the control group in this region of the brain. This result suggests that non-pathological levels of A β are unaffected by treatment.

[0138] APP concentration was also determined by ELISA in the cortex and cerebellum from treated and control mice. Two different APP assays were utilized. The first, designated APP- α /FL, recognizes both APP-alpha (α , the secreted form of APP which has been cleaved within the A β sequence), and full-length forms (FL) of APP, while the second recognizes only APP- α . In contrast to the treatment-associated diminution of A β in a subset of treatment groups, the levels of APP were unchanged in all of the treated compared to the control animals. These results indicate that the immunizations with A β peptides are not depleting APP; rather the treatment effect is specific to A β .

[0139] In summary, total A β and A β 1-42 levels were significantly reduced in the cortex by treatment with AN1792, rodent A β 1-42 or A β 1-5 conjugate. In the hippocampus, total A β was significantly reduced only by AN1792 treatment. No other treatment-associated changes in A β or APP levels in the hippocampal, cortical or cerebellar regions were significant.

2. Histochemical Analyses

[0140] Brains from a subset of six groups were prepared for immunohistochemical analysis, three groups immunized with the A β peptide conjugates A β 1-5, A β 1-12, and A β 13-28; two groups immunized with the full length A β aggregates AN1792 and AN1528 and the PBS-treated control group. The results of image analyses of the amyloid burden in brain sections from these groups are shown in Fig. 12. There were significant reductions of amyloid burden in the cortical regions of three of the treatment groups versus control animals. The greatest reduction of amyloid burden was observed in the group receiving AN1792 where the mean value was reduced by 97% ($p = 0.001$). Significant reductions were also observed for those animals treated with AN1528 (95%, $p = 0.005$) and the A β 1-5 peptide conjugate (67%, $p = 0.02$).

[0141] The results obtained by quantitation of total A β or A β 1-42 by ELISA and amyloid burden by image analysis differ to some extent. Treatment with AN1528 had a significant impact on the level of cortical amyloid burden when measured by quantitative image analysis but not on the concentration of total A β in the same region when measured by ELISA. The difference between these two results is likely to be due to the specificities of the assays. Image analysis measures only insoluble A β aggregated into plaques. In contrast, the ELISA measures all forms of A β , both soluble and insoluble, monomeric and aggregated. Since the disease pathology is thought to be associated with the insoluble plaque-associated form of A β , the image analysis technique may have more sensitivity to reveal treatment effects. However since the ELISA is a more rapid and easier assay, it is very useful for screening purposes. Moreover it may reveal that

the treatment-associated reduction of A β is greater for plaque-associated than total A β .

[0142] To determine if the A β -specific antibodies elicited by immunization in the treated animals reacted with deposited brain amyloid, a subset of the sections from the treated animals and the control mice were reacted with an antibody specific for mouse IgG. In contrast to the PBS group, A β -containing plaques were coated with endogenous IgG for animals immunized with the A β peptide conjugates A β 1-5, A β 1-12, and A β 13-28; and the full length A β aggregates AN1792 and AN1528. Brains from animals immunized with the other A β peptides or the APP peptide pBx6 were not analyzed by this assay.

3. Measurement of Antibody Titers

[0143] Mice were bled four to seven days following each immunization starting after the second immunization, for a total of five bleeds. Antibody titers were measured as A β 1-42-binding antibody using a sandwich ELISA with plastic multi-well plates coated with A β 1-42. As shown in Fig. 13, peak antibody titers were elicited following the fourth dose for those four vaccines which elicited the highest titers of AN1792-specific antibodies: AN1792 (peak GMT: 94,647), AN1528 (peak GMT: 88,231), A β 1-12 conjugate (peak GMT: 47,216) and rodent A β 1-42 (peak GMT: 10,766). Titers for these groups declined somewhat following the fifth and sixth doses. For the remaining five immunogens, peak titers were reached following the fifth or the sixth dose and these were of much lower magnitude than those of the four highest titer groups: A β 1-5 conjugate (peak GMT: 2,356), pBx6 (peak GMT: 1,986), A β 13-28 conjugate (peak GMT: 1,183), A β 33-42 conjugate (peak GMT: 658), A β 25-35 (peak GMT: 125). Antibody titers were also measured against the homologous peptides using the same ELISA sandwich format for a subset of the immunogens, those groups immunized with A β 1-5, A β 13-28, A β 25-35, A β 33-42 or rodent A β 1-42. These titers were about the same as those measured against A β 1-42 except for the rodent A β 1-42 immunogen in which case antibody titers against the homologous immunogen were about two-fold higher. The magnitude of the AN1792-specific antibody titer of individual animals or the mean values of treatment groups did not correlate with efficacy measured as the reduction of A β in the cortex.

4. Lymphoproliferative Responses

[0144] A β -dependent lymphoproliferation was measured using spleen cells harvested approximately one week following the final, sixth, immunization. Freshly harvested cells, 10^5 per well, were cultured for 5 days in the presence of A β 1-40 at a concentration of 5 μ M for stimulation. Cells from a subset of seven of the ten groups were also cultured in the presence of the reverse peptide, A β 40-1. As a positive control, additional cells were cultured with the T cell mitogen, PHA, and, as a negative control, cells were cultured without added peptide.

[0145] Lymphocytes from a majority of the animals proliferated in response to PHA. There were no significant responses to the A β 40-1 reverse peptide. Cells from animals immunized with the larger aggregated A β peptides, AN1792, rodent A β 1-42 and AN1528 proliferated robustly when stimulated with A β 1-40 with the highest cpm in the recipients of AN1792. One animal in each of the groups immunized with A β 1-12 conjugate, A β 13-28 conjugate and A β 25-35 proliferated in response to A β 1-40. The remaining groups receiving A β 1-5 conjugate, A β 33-42 conjugate pBx6 or PBS had no animals with an A β -stimulated response. These results are summarized in Table 5 below.

Table 5			
Immunogen	Conjugate	A β Amino Acids	Responders
A β 1-5	yes	5-mer	0/7
A β 1-12	yes	12-mer	1/8
A β 13-28	yes	16-mer	1/9
A β 25-35		11-mer	1/9
A β 33-42	yes	10-mer	0/10
A β 1-40		40-mer	5/8
A β 1-42		42-mer	9/9
r A β 1-42		42-mer	8/8
pBx6			0/8
PBS		0-mer	0/8

[0146] These results show that AN1792 and AN1528 stimulate strong T cell responses, most likely of the CD4⁺ phenotype. The absence of an A β -specific T cell response in animals immunized with A β 1-5 is not surprising since peptide epitopes recognized by CD4⁺ T cells are usually about 15 amino acids in length, although shorter peptides can sometimes function with less efficiency. Thus the majority of helper T cell epitopes for the four conjugate peptides are likely to reside in the IgG conjugate partner, not in the A β region. This hypothesis is supported by the very low incidence of proliferative responses for animals in each of these treatment groups. Since the A β 1-5 conjugate was effective at significantly reducing the level of A β in the brain, in the apparent absence of A β -specific T cells, the key effector immune response induced by immunization with this peptide appears to be antibody.

[0147] Lack of T-cell and low antibody response from fusion peptide pBx6, encompassing APP amino acids 592-695 including all of the A β residues may be due to the poor immunogenicity of this particular preparation. The poor immunogenicity of the A β 25-35 aggregate is likely due to the peptide being too small to be likely to contain a good T cell epitope to help the induction of an antibody response. If this peptide were conjugated to a carrier protein, it would probably be more immunogenic.

V. Preparation of Polyclonal Antibodies for Passive Protection

[0148] 20 non-transgenic mice are immunized with A β or other immunogen, optionally plus adjuvant, and are euthanized at 4-5 months. Blood is collected from immunized mice. Optionally, IgG is separated from other blood components. Antibody specific for the immunogen may be partially purified by affinity chromatography. An average of about 0.5-1 mg of immunogen-specific antibody is obtained per mouse, giving a total of 5-10 mg.

VI. Passive Immunization with Antibodies to A β

[0149] Groups of 7-9 month old PDAPP mice each are injected with 0.5 mg in PBS of polyclonal anti-A β or specific anti-A β monoclonals as shown below. All antibody preparations are purified to have low endotoxin levels. Monoclonals can be prepared against a fragment by injecting the fragment or longer form of A β into a mouse, preparing hybridomas and screening the hybridomas for an antibody that specifically binds to a desired fragment of A β without binding to other nonoverlapping fragments of A β .

Table 6

Antibody	Epitope
2H3	A β 1-12
10D5	A β 1-12
266	A β 13-28
21F12	A β 33-42
Mouse polyclonal anti-human A β 42	Anti-Aggregated A β 42

[0150] Mice are injected ip as needed over a 4 month period to maintain a circulating antibody concentration measured by ELISA titer of greater than 1/1000 defined by ELISA to A β 42 or other immunogen. Titers are monitored as above and mice are euthanized at the end of 4 months of injections. Histochemistry, A β levels and toxicology are performed post mortem. Ten mice are used per group.

VII. Comparison of Different Adjuvants

[0151] This examples compares CFA, alum, an oil-in water emulsion and MPL for capacity to stimulate an immune response.

A. Materials and Methods

1. Study Design

[0152] One hundred female Hartley strain six-week old guinea pigs, obtained from Elm Hill, were sorted into ten groups to be immunized with AN1792 or a palmitoylated derivative thereof combined with various adjuvants. Seven groups received injections of AN1792 (33 μ g unless otherwise specified) combined with a) PBS, b) Freund's adjuvant, c) MPL,

d) squalene, e) MPL/squalene f) low dose alum, or g) high dose alum (300 µg AN1792). Two groups received injections of a palmitoylated derivative of AN1792 (33 µg) combined with a) PBS or b) squalene. A final, tenth group received PBS alone without antigen or additional adjuvant. For the group receiving Freund's adjuvant, the first dose was emulsified with CFA and the remaining four doses with IFA. Antigen was administered at a dose of 33 µg for all groups except the high dose alum group, which received 300 µg of AN1792. Injections were administered intraperitoneally for CFA/IFA and intramuscularly in the hind limb quadriceps alternately on the right and left side for all other groups. The first three doses were given on a biweekly schedule followed by two doses at a monthly interval. Blood was drawn six to seven days following each immunization, starting after the second dose, for measurement of antibody titers.

2. Preparation of Immunogens

[0153] Two mg Aβ42 (California Peptide, Lot ME0339) was added to 0.9 ml of deionized water and the mixture was vortexed to generate a relatively uniform suspension. A 100 µl aliquot of 10X PBS (1X PBS, 0.15 M NaCl, 0.01 M sodium phosphate, pH 7.5) was added. The suspension was vortexed again and incubated overnight at 37 °C for use the next day. Unused Aβ1-42 was stored with desiccant as a lyophilized powder at -20 °C.

[0154] A palmitoylated derivative of AN1792 was prepared by coupling palmitic anhydride, dissolved in dimethyl formamide, to the amino terminal residue of AN1792 prior to removal of the nascent peptide from the resin by treatment with hydrofluoric acid.

[0155] To prepare vaccine doses with Complete Freund's adjuvant (CFA) (group 2), 33 µg of AN1792 in 200 µl PBS was emulsified 1:1 (vol:vol) with CFA in a final volume of 400 µl for the first immunization. For subsequent immunizations, the antigen was similarly emulsified with Incomplete Freund's adjuvant (IFA) .

[0156] To prepare vaccine doses with MPL for groups 5 and 8, lyophilized powder (Ribi ImmunoChem Research, Inc., Hamilton, MT) was added to 0.2% aqueous triethylamine to a final concentration of 1 mg/ml and vortexed. The mixture was heated to 65 to 70 °C for 30 sec to create a slightly opaque uniform suspension of micelles. The solution was freshly prepared for each set of injections. For each injection in group 5, 33 µg of AN1792 in 16.5 µl PBS, 50 µg of MPL (50 µl) and 162 µl of PBS were mixed in a borosilicate tube immediately before use.

[0157] To prepare vaccine doses with the low oil-in-water emulsion, AN1792 in PBS was added to 5% squalene, 0.5% Tween 80, 0.5% Span 85 in PBS to reach a final single dose concentration of 33 µg AN1792 in 250 µl (group 6). The mixture was emulsified by passing through a two-chambered hand-held device 15 to 20 times until the emulsion droplets appeared to be about equal in diameter to a 1.0 µm diameter standard latex bead when viewed under a microscope. The resulting suspension was opalescent, milky white. The emulsions were freshly prepared for each series of injections. For group 8, MPL in 0.2% triethylamine was added at a concentration of 50 µg per dose to the squalene and detergent mixture for emulsification as noted above. For the palmitoyl derivative (group 7), 33 µg per dose of palmitoyl-NH-Aβ1-42 was added to squalene and vortexed. Tween 80 and Span 85 were then added with vortexing. This mixture was added to PBS to reach final concentrations of 5% squalene, 0.5% Tween 80, 0.5% Span 85 and the mixture was emulsified as noted above.

[0158] To prepare vaccine doses with alum (groups 9 and 10), AN1792 in PBS was added to Alhydrogel (aluminum hydroxide gel, Accurate, Westbury, NY) to reach concentrations of 33 µg (low dose, group 9) or 300 µg (high dose, group 10) AN1792 per 5 mg of alum in a final dose volume of 250 µl. The suspension was gently mixed for 4 hr at RT.

3. Measurement of Antibody Titers

[0159] Guinea pigs were bled six to seven days following immunization starting after the second immunization for a total of four bleeds. Antibody titers against Aβ42 were measured by ELISA as described in General Materials and Methods.

4. Tissue Preparation

[0160] After about 14 weeks, all guinea pigs were administered CO₂. Cerebrospinal fluid was collected and the brains were removed and three brain regions (hippocampus, cortex and cerebellum) were dissected and used to measure the concentration of total Aβ protein using ELISA.

B. Results

1. Antibody Responses

[0161] There was a wide range in the potency of the various adjuvants when measured as the antibody response to AN1792 following immunization. As shown in Fig. 14, when AN1792 was administered in PBS, no antibody was detected following two or three immunizations and negligible responses were detected following the fourth and fifth doses with

geometric mean titers (GMTs) of only about 45. The o/w emulsion induced modest titers following the third dose (GMT 255) that were maintained following the fourth dose (GMT 301) and fell with the final dose (GMT 54). There was a clear antigen dose response for AN1792 bound to alum with 300 μ g being more immunogenic at all time points than 33 μ g. At the peak of the antibody response, following the fourth immunization, the difference between the two doses was 43% with GMTs of about 1940 (33 μ g) and 3400 (300 μ g). The antibody response to 33 μ g AN1792 plus MPL was very similar to that generated with almost a ten-fold higher dose of antigen (300 μ g) bound to alum. The addition of MPL to an o/w emulsion decreased the potency of the vaccine relative to that with MPL as the sole adjuvant by as much as 75%. A palmitoylated derivative of AN1792 was completely non-immunogenic when administered in PBS and gave modest titers when presented in an o/w emulsion with GMTs of 340 and 105 for the third and fourth bleeds. The highest antibody titers were generated with Freund's adjuvant with a peak GMT of about 87,000, a value almost 30-fold greater than the GMTs of the next two most potent vaccines, MPL and high dose AN1792/alum.

[0162] The most promising adjuvants identified in this study are MPL and alum. Of these two, MPL appears preferable because a 10-fold lower antigen dose was required to generate the same antibody response as obtained with alum. The response can be increased by increasing the dose of antigen and /or adjuvant and by optimizing the immunization schedule. The o/w emulsion was a very weak adjuvant for AN1792 and adding an o/w emulsion to MPL adjuvant diminished the intrinsic adjuvant activity of MPL alone.

2. A β Levels In The Brain

[0163] At about 14 weeks the guinea pigs were deeply anesthetized, the cerebrospinal fluid (CSF) was drawn and brains were excised from animals in a subset of the groups, those immunized with Freund's adjuvant (group 2), MPL (group 5), alum with a high dose, 300 μ g, of AN1792 (group 10) and the PBS immunized control group (group 3). To measure the level of A β peptide, one hemisphere was dissected and homogenates of the hippocampal, cortical, and cerebellar regions were prepared in 5 M guanidine. These were diluted and quantitated by comparison to a series of dilutions of A β standard protein of known concentrations in an ELISA format. The levels of A β protein in the hippocampus, the cortex and the cerebellum were very similar for all four groups despite the wide range of antibody responses to A β elicited by these vaccines. Mean A β levels of about 25 ng/g tissue were measured in the hippocampus, 21 ng/g in the cortex, and 12 ng/g in the cerebellum. Thus, the presence of a high circulating antibody titer to A β for almost three months in some of these animals did not alter the total A β levels in their brains. The levels of A β in the CSF were also quite similar between the groups. The lack of large effect of AN1792 immunization on endogenous A β indicates that the immune response is focused on pathological formations of A β .

VIII. Immune Response to Different Adjuvants in Mice

[0164] Six-week old female Swiss Webster mice were used for this study with 10-13 animals per group. Immunizations were given on days 0, 14, 28, 60, 90 and 20 administered subcutaneously in a dose volume of 200 μ l. PBS was used as the buffer for all formulations. Animals were bleed seven days following each immunization starting after the second dose for analysis of antibody titers by ELISA. The treatment regime of each group is summarized in Table 7.

Table 7

Experimental Design of Betabloc Study 010					
Group	N ^a	Adjuvant ^b	Dose	Antigen	Dose (μ g)
1	10	MPL	12.5 μ g	AN1792	33
2	10	MPL	25 μ g	AN1792	33
3	10	MPL	50 μ g	AN1792	33
4	13	MPL	125 μ g	AN1792	33
5	13	MPL	50 μ g	AN 1792	150
6	13	MPL	50 μ g	AN1528	33
7	10	PBS		AN1792	33
8	10	PBS		none	
9	10	Squalene emulsified	5%	AN1792	33
10	10	Squalene admixed	5%	AN1792	33

EP 1 690 547 B1

(continued)

Experimental Design of Betabloc Study 010					
Group	N ^a	Adjuvant ^b	Dose	Antigen	Dose (μg)
11	10	Alum	2 mg	AN 1792	33
12	13	MPL + Alum	50 μg/2 mg	AN1792	33
13	10	QS21	5 μg	AN1792	33
14	10	QS21	10 μg	AN1792	33
15	10	QS21	25 μg	AN1792	33
16	13	QS21	25 μg	AN1792	150
17	13	QS21	25 μg	AN 1528	33
18	13	QS21 + MPL	25 μg/50 μg	AN 1792	33
19	13	QS21 + Alum	25 μg/2 mg	AN1792	33
Footnotes: ^a Number of mice in each group at the initiation of the experiment. ^b The adjuvants are noted. The buffer for all these formulations was PBS. For group 8, there was no adjuvant and no antigen.					

[0165] The ELISA titers of antibodies against Aβ42 in each group are shown in Table 8 below.

Table 8.

Geometric Mean Antibody Titers					
Week of Bleed					
Treatment Group	2.9	5.0	8.7	12.9	16.7
1	248	1797	2577	6180	4177
2	598	3114	3984	5287	6878
3	1372	5000	7159	12333	12781
4	1278	20791	14368	20097	25631
5	3288	26242	13229	9315	23742
6	61	2536	2301	1442	4504
7	37	395	484	972	2149
8	25	25	25	25	25
9	25	183	744	952	1823
10	25	89	311	513	817
11	29	708	2618	2165	3666
12	198	1458	1079	612	797
13	38	433	566	1080	626
14	104	541	3247	1609	838
15	212	2630	2472	1224	1496
16	183	2616	6680	2085	1631
17	28	201	375	222	1540
18	31699	15544	23095	6412	9059
19	63	243	554	299	441

[0166] The table shows that the highest titers were obtained for groups 4, 5 and 18, in which the adjuvants were 125 µg MPL, 50 µg MPL and QS21 plus MPL.

IX. Therapeutic Efficacy of Different Adjuvants

[0167] A therapeutic efficacy study was conducted in PDAPP transgenic mice with a set of adjuvants suitable for use in humans to determine their ability to potentiate immune responses to Aβ and to induce the immune-mediated clearance of amyloid deposits in the brain.

[0168] One hundred eighty male and female, 7.5- to 8.5-month old heterozygous PDAPP transgenic mice were obtained from Charles River Laboratories. The mice were sorted into nine groups containing 15 to 23 animals per group to be immunized with AN1792 or AN1528 combined with various adjuvants. Animals were distributed to match the gender, age, and parentage of the animals within the groups as closely as possible. The adjuvants included alum, MPL, and QS21, each combined with both antigens, and Freund's adjuvant (FA) combined with only AN1792. An additional group was immunized with AN1792 formulated in PBS buffer plus the preservative thimerosal without adjuvant. A ninth group was immunized with PBS alone as a negative control.

[0169] Preparation of aggregated Aβ peptides: human Aβ1-40 (AN1528; California Peptides Inc., Napa, CA; Lot ME0541) and human Aβ1-42 (AN1792; California Peptides Inc., Lot ME0439) peptides were freshly solubilized for the preparation of each set of injections from lyophilized powders that had been stored desiccated at -20 °C. For this purpose, two mg of peptide were added to 0.9 ml of deionized water and the mixture was vortexed to generate a relatively uniform solution or suspension. AN1528 was soluble at this step, in contrast to AN1792. A 100 µl aliquot of 10X PBS (1X PBS: 0.15 M NaCl, 0.01 M sodium phosphate, pH 7.5) was then added at which point AN1528 began to precipitate. The suspensions were vortexed again and incubated overnight at 37 °C for use the next day.

[0170] To prepare vaccine doses with alum (Groups 1 and 5), Aβ peptide in PBS was added to Alhydrogel (two percent aqueous aluminum hydroxide gel, Sargeant, Inc., Clifton, NJ) to reach concentrations of 100 µg Aβ peptide per 1 mg of alum. 10X PBS was added to a final dose volume of 200 µl in 1X PBS. The suspension was then gently mixed for approximately 4 hr at RT prior to injection.

[0171] To prepare vaccine doses for with MPL (Groups 2 and 6), lyophilized powder (Ribi ImmunoChem Research, Inc., Hamilton, MT; Lot 67039-E0896B) was added to 0.2% aqueous triethylamine to a final concentration of 1 mg/ml and vortexed. The mixture was heated to 65 to 70 °C for 30 sec to create a slightly opaque uniform suspension of micelles. The solution was stored at 4 °C. For each set of injections, 100 µg of peptide per dose in 50 µl PBS, 50 µg of MPL per dose (50 µl) and 100 µl of PBS per dose were mixed in a borosilicate tube immediately before use.

[0172] To prepare vaccine doses with QS21 (Groups 3 and 7), lyophilized powder (Aquila, Framingham, MA; Lot A7018R) was added to PBS, pH 6.6-6.7 to a final concentration of 1 mg/ml and vortexed. The solution was stored at -20 °C. For each set of injections, 100 µg of peptide per dose in 50 µl PBS, 25 µg of QS21 per dose in 25 µl PBS and 125 µl of PBS per dose were mixed in a borosilicate tube immediately before use.

[0173] To prepare vaccine doses with Freund's Adjuvant (Group 4), 100 µg of AN1792 in 200 µl PBS was emulsified 1:1 (vol:vol) with Complete Freund's Adjuvant (CFA) in a final volume of 400 µl for the first immunization. For subsequent immunizations, the antigen was similarly emulsified with Incomplete Freund's Adjuvant (IFA). For the vaccines containing the adjuvants alum, MPL or QS21, 100 µg per dose of AN1792 or AN1528 was combined with alum (1 mg per dose) or MPL (50 µg per dose) or QS21 (25 µg per dose) in a final volume of 200 µl PBS and delivered by subcutaneous inoculation on the back between the shoulder blades. For the group receiving FA, 100 µg of AN1792 was emulsified 1:1 (vol:vol) with Complete Freund's adjuvant (CFA) in a final volume of 400 µl and delivered intraperitoneally for the first immunization, followed by a boost of the same amount of immunogen in Incomplete Freund's adjuvant (IFA) for the subsequent five doses. For the group receiving AN1792 without adjuvant, 10 µg AN1792 was combined with 5 µg thimerosal in a final volume of 50 µl PBS and delivered subcutaneously. The ninth, control group received only 200 µl PBS delivered subcutaneously. Immunizations were given on a biweekly schedule for the first three doses, then on a monthly schedule thereafter on days 0, 16, 28, 56, 85 and 112. Animals were bled six to seven days following each immunization starting after the second dose for the measurement of antibody titers. Animals were euthanized approximately one week after the final dose. Outcomes were measured by ELISA assay of Aβ and APP levels in brain and by immunohistochemical evaluation of the presence of amyloid plaques in brain sections. In addition, Aβ-specific antibody titers, and Aβ-dependent proliferative and cytokine responses were determined.

[0174] Table 9 shows that the highest antibody titers to Aβ1-42 were elicited with FA and AN1792, titers which peaked following the fourth immunization (peak GMT: 75,386) and then declined by 59% after the final, sixth immunization. The peak mean titer elicited by MPL with AN1792 was 62% lower than that generated with FA (peak GMT: 28,867) and was also reached early in the immunization scheme, after 3 doses, followed by a decline to 28% of the peak value after the sixth immunization. The peak mean titer generated with QS21 combined with AN1792 (GMT: 1,511) was about 5-fold lower than obtained with MPL. In addition, the kinetics of the response were slower, since an additional immunization was required to reach the peak response. Titers generated by alum-bound AN1792 were marginally greater than those

obtained with QS21 and the response kinetics were more rapid. For AN1792 delivered in PBS with thimerosal the frequency and size of titers were barely greater than that for PBS alone. The peak titers generated with MPL and AN1528 (peak GMT 3099) were about 9-fold lower than those with AN1792. Alum-bound AN1528 was very poorly immunogenic with low titers generated in only some of the animals. No antibody responses were observed in the control animals immunized with PBS alone.

Table 9

Geometric Mean Antibody Titers ^a					
Week of Bleed					
Treatment	3.3	5.0	9.0	13.0	17.0
Alum/ AN1792	102 (12/21) ^b	1,081 (17/20)	2,366 (21/21)	1,083 (19/21)	572 (18/21)
MPL/ AN1792	6241 (21/21)	28,867 (21/21)	1,1242 (21/21)	5,665 (20/20)	8,204 (20/20)
QS21/ AN1792	30 (1/20)	227 (10/19)	327 (10/19)	1,511 (17/18)	1,188 (14/18)
CFA/ AN1792	10,076 (15/15)	61,279 (15/15)	75,386 (15/15)	41,628 (15/15)	30,574 (15/15)
Alum/ AN1528	25 (0/21)	33 (1/21)	39 (3/20)	37 (1/20)	31 (2/20)
MPL/ AN1528	184 (15/21)	2,591 (20/21)	1,653 (21/21)	1,156 (20/20)	3,099 (20/20)
QS21/ AN1528	29 (1/22)	221 (13/22)	51 (4/22)	820 (20/22)	2,994 (21/22)
PBS plus Thimerosal	25 (0/16)	33 (2/16)	39 (4/16)	37 (3/16)	47 (4/16)
PBS	25 (0/16)	25 (0/16)	25 (0/15)	25 (0/12)	25 (0/16)
Footnotes:					
^a Geometric mean antibody titers measured against A β 1-42					
^b Number of responders per group					

[0175] The results of AN1792 or AN1592 treatment with various adjuvants, or thimerosal on cortical amyloid burden in 12-month old mice determined by ELISA are shown in Fig. 15. In PBS control PDAPP mice, the median level of total A β in the cortex at 12 months was 1,817 ng/g. Notably reduced levels of A β were observed in mice treated with AN1792 plus CFA/IFA, AN1792 plus alum, AN1792 plus MPL and QS21 plus AN1792. The reduction reached statistical significance ($p < 0.05$) only for AN1792 plus CFA/IFA. However, as shown in Examples I and III, the effects of immunization in reducing A β levels become substantially greater in 15 month and 18 month old mice. Thus, it is expected that at least the AN1792 plus alum, AN1792 plus MPL and AN1792 plus QS21 compositions will achieve statistical significance in treatment of older mice. By contrast, the AN1792 plus the preservative thimerosal showed a median level of A β about the same as that in the PBS treated mice. Similar results were obtained when cortical levels of A β 42 were compared. The median level of A β 42 in PBS controls was 1624 ng/g. Notably reduced median levels of 403, 1149, 620 and 714 were observed in the mice treated with AN1792 plus CFA/IFA, AN1792 plus alum, AN1792 plus MPL and AN1792 plus QS21 respectively, with the reduction achieving statistical significance ($p = 0.05$) for the AN1792 CFA/IFA treatment group. The median level in the AN1792 thimerosal treated mice was 1619 ng/g A β 42.

X. Toxicity Analysis

[0176] Tissues were collected for histopathologic examination at the termination of studies described in Examples 2, 3 and 7. In addition, hematology and clinical chemistry were performed on terminal blood samples from Examples 3 and

7. Most of the major organs were evaluated, including brain, pulmonary, lymphoid, gastrointestinal, liver, kidney, adrenal and gonads. Although sporadic lesions were observed in the study animals, there were no obvious differences, either in tissues affected or lesion severity, between AN1792 treated and untreated animals. There were no unique histopathological lesions noted in AN-1782-immunized animals compared to PBS-treated or untreated animals. There were also no differences in the clinical chemistry profile between adjuvant groups and the PBS treated animals in Example 7. Although there were significant increases in several of the hematology parameters between animals treated with AN1792 and Freund's adjuvant in Example 7 relative to PBS treated animals, these type of effects are expected from Freund's adjuvant treatment and the accompanying peritonitis and do not indicate any adverse effects from AN1792 treatment. Although not part of the toxicological evaluation, PDAPP mouse brain pathology was extensively examined as part of the efficacy endpoints. No sign of treatment related adverse effect on brain morphology was noted in any of the studies. These results indicate that AN1792 treatment is well tolerated and at least substantially free of side effects.

XI. Prevention and Treatment of Subjects

[0177] A single-dose phase I trial is performed to determine safety. A therapeutic agent is administered in increasing dosages to different patients starting from about 0.01 the level of presumed efficacy, and increasing by a factor of three until a level of about 10 times the effective mouse dosage is reached.

[0178] A phase II trial is performed to determine therapeutic efficacy. Patients with early to mid Alzheimer's Disease defined using Alzheimer's disease and Related Disorders Association (ADRD) criteria for probable AD are selected. Suitable patients score in the 12-26 range on the Mini-Mental State Exam (MMSE). Other selection criteria are that patients are likely to survive the duration of the study and lack complicating issues such as use of concomitant medications that may interfere. Baseline evaluations of patient function are made using classic psychometric measures, such as the MMSE, and the ADAS, which is a comprehensive scale for evaluating patients with Alzheimer's Disease status and function. These psychometric scales provide a measure of progression of the Alzheimer's condition. Suitable qualitative life scales can also be used to monitor treatment. Disease progression can also be monitored by MRI. Blood profiles of patients can also be monitored including assays of immunogen-specific antibodies and T-cells responses.

[0179] Following baseline measures, patients begin receiving treatment. They are randomized and treated with either therapeutic agent or placebo in a blinded fashion. Patients are monitored at least every six months. Efficacy is determined by a significant reduction in progression of a treatment group relative to a placebo group.

[0180] A second phase II trial is performed to evaluate conversion of patients from non-Alzheimer's Disease early memory loss, sometimes referred to as age-associated memory impairment (AAMI), to probable Alzheimer's disease as defined as by ADRD criteria. Patients with high risk for conversion to Alzheimer's Disease are selected from a non-clinical population by screening reference populations for early signs of memory loss or other difficulties associated with pre-Alzheimer's symptomatology, a family history of Alzheimer's Disease, genetic risk factors, age, sex, and other features found to predict high-risk for Alzheimer's Disease. Baseline scores on suitable metrics including the MMSE and the ADAS together with other metrics designed to evaluate a more normal population are collected. These patient populations are divided into suitable groups with placebo comparison against dosing alternatives with the agent. These patient populations are followed at intervals of about six months, and the endpoint for each patient is whether or not he or she converts to probable Alzheimer's Disease as defined by ADRD criteria at the end of the observation.

XII. General Materials and Methods

1. Measurement of Antibody Titers

[0181] Mice were bled by making a small nick in the tail vein and collecting about 200 μ l of blood into a microfuge tube. Guinea pigs were bled by first shaving the back hock area and then using an 18 gauge needle to nick the metatarsal vein and collecting the blood into microfuge tubes. Blood was allowed to clot for one hr at room temperature (RT), vortexed, then centrifuged at 14,000 x g for 10 min to separate the clot from the serum. Serum was then transferred to a clean microfuge tube and stored at 4° C until titrated.

[0182] Antibody titers were measured by ELISA. 96-well microtiter plates (Costar EIA plates) were coated with 100 μ l of a solution containing either 10 μ g/ml either A β 42 or SAPP or other antigens as noted in each of the individual reports in Well Coating Buffer (0.1 M sodium phosphate, pH 8.5, 0.1% sodium azide) and held overnight at RT. The wells were aspirated and sera were added to the wells starting at a 1/100 dilution in Specimen Diluent (0.014 M sodium phosphate, pH 7.4, 0.15 M NaCl, 0.6% bovine serum albumin, 0.05% thimerosal). Seven serial dilutions of the samples were made directly in the plates in three-fold steps to reach a final dilution of 1/218,700. The dilutions were incubated in the coated-plate wells for one hr at RT. The plates were then washed four times with PBS containing 0.05% Tween 20. The second antibody, a goat anti-mouse Ig conjugated to horseradish peroxidase (obtained from Boehringer Mannheim), was added to the wells as 100 μ l of a 1/3000 dilution in Specimen Diluent and incubated for one hr at RT. Plates

were again washed four times in PBS, Tween 20. To develop the chromogen, 100 μ l of Slow TMB (3,3',5,5'-tetramethyl benzidine obtained from Pierce Chemicals) was added to each well and incubated for 15 min at RT. The reaction was stopped by the addition of 25 μ l of 2 M H_2SO_4 . The color intensity was then read on a Molecular Devices Vmax at (450 nm - 650 nm).

[0183] Titers were defined as the reciprocal of the dilution of serum giving one half the maximum OD. Maximal OD was generally taken from an initial 1/100 dilution, except in cases with very high titers, in which case a higher initial dilution was necessary to establish the maximal OD. If the 50% point fell between two dilutions, a linear extrapolation was made to calculate the final titer. To calculate geometric mean antibody titers, titers less than 100 were arbitrarily assigned a titer value of 25.

2. Lymphocyte proliferation assay

[0184] Mice were anesthetized with isoflurane. Spleens were removed and rinsed twice with 5 ml PBS containing 10% heat-inactivated fetal bovine serum (PBS-FBS) and then homogenized in a 50 μ Centricon unit (Dako A/S, Denmark) in 1.5 ml PBS-FBS for 10 sec at 100 rpm in a Medimachine (Dako) followed by filtration through a 100 μ pore size nylon mesh. Splenocytes were washed once with 15 ml PBS-FBS, then pelleted by centrifugation at 200 x g for 5 min. Red blood cells were lysed by resuspending the pellet in 5 mL buffer containing 0.15 M NH_4Cl , 1 M $KHCO_3$, 0.1 M NaEDTA, pH 7.4 for five min at RT. Leukocytes were then washed as above. Freshly isolated spleen cells (10^5 cells per well) were cultured in triplicate sets in 96-well U-bottomed tissue culture-treated microtiter plates (Corning, Cambridge, MA) in RPMI 1640 medium (JRH Biosciences, Lenexa, KS) supplemented with 2.05 mM L-glutamine, 1% Penicillin/Streptomycin, and 10% heat-inactivated FBS, for 96 hr at 37°C. Various A β peptides, A β 1-16, A β 1-40, A β 1-42 or A β 40-1 reverse sequence protein were also added at doses ranging from 5 μ M to 0.18 μ M in four steps. Cells in control wells were cultured with Concanavalin A (Con A) (Sigma, cat. # C-5275, at 1 μ g/ml) without added protein. Cells were pulsed for the final 24 hr with 3H -thymidine (1 μ Ci/well obtained from Amersham Corp., Arlington Heights IL). Cells were then harvested onto UniFilter plates and counted in a Top Count Microplate Scintillation Counter (Packard Instruments, Downers Grove, IL). Results are expressed as counts per minute (cpm) of radioactivity incorporated into insoluble macromolecules.

4. Brain Tissue Preparation

[0185] After euthanasia, the brains were removed and one hemisphere was prepared for immunohistochemical analysis, while three brain regions (hippocampus, cortex and cerebellum) were dissected from the other hemisphere and used to measure the concentration of various A β proteins and APP forms using specific ELISAs (Johnson-Wood et al., *supra*).

[0186] Tissues destined for ELISAs were homogenized in 10 volumes of ice-cold guanidine buffer (5.0 M guanidine-HCl, 50 mM Tris-HCl, pH 8.0). The homogenates were mixed by gentle agitation using an Adams Nutator (Fisher) for three to four hr at RT, then stored at -20°C prior to quantitation of A β and APP. Previous experiments had shown that the analytes were stable under this storage condition, and that synthetic A β protein (Bachem) could be quantitatively recovered when spiked into homogenates of control brain tissue from mouse littermates (Johnson-Wood et al., *supra*).

5. Measurement of A β Levels

[0187] The brain homogenates were diluted 1:10 with ice cold Casein Diluent (0.25% casein, PBS, 0.05% sodium azide, 20 μ g/ml aprotinin, 5 mM EDTA pH 8.0, 10 μ g/ml leupeptin) and then centrifuged at 16,000 x g for 20 min at 4°C. The synthetic A β protein standards (1-42 amino acids) and the APP standards were prepared to include 0.5 M guanidine and 0.1% bovine serum albumin (BSA) in the final composition. The "total" A β sandwich ELISA utilizes monoclonal antibody (mAb) 266, specific for amino acids 13-28 of A β (Seubert, et al.), as the capture antibody, and biotinylated mAb 3D6, specific for amino acids 1-5 of A β (Johnson-Wood, et al.), as the reporter antibody. The 3D6 mAb does not recognize secreted APP or full-length APP, but detects only A β species with an amino-terminal aspartic acid. This assay has a lower limit of sensitivity of ~50 μ g/ml (11 pM) and shows no cross-reactivity to the endogenous murine A β protein at concentrations up to 1 ng/ml (Johnson-Wood et al., *supra*).

[0188] The A β 1-42 specific sandwich ELISA employs mAb 21F12, specific for amino acids 33-42 of A β (Johnson-Wood, et al.), as the capture antibody. Biotinylated mAb 3D6 is also the reporter antibody in this assay which has a lower limit of sensitivity of about 125 μ g/ml (28 pM, Johnson-Wood et al.). For the A β ELISAs, 100 μ l of either mAb 266 (at 10 μ g/ml) or mAb 21F12 at (5 μ g/ml) was coated into the wells of 96-well immunoassay plates (Costar) by overnight incubation at RT. The solution was removed by aspiration and the wells were blocked by the addition of 200 μ l of 0.25% human serum albumin in PBS buffer for at least 1 hr at RT. Blocking solution was removed and the plates were stored desiccated at 4°C until used. The plates were rehydrated with Wash Buffer [Trisbuffered saline (0.15 M NaCl, 0.01 M

Tris-HCl, pH 7.5), plus 0.05% Tween 20] prior to use. The samples and standards were added in triplicate aliquots of 100 μ l per well and then incubated overnight at 4° C. The plates were washed at least three times with Wash Buffer between each step of the assay. The biotinylated mAb 3D6, diluted to 0.5 μ g/ml in Casein Assay Buffer (0.25% casein, PBS, 0.05% Tween 20, pH 7.4), was added and incubated in the wells for 1 hr at RT. An avidin-horseradish peroxidase conjugate, (Avidin-HRP obtained from Vector, Burlingame, CA), diluted 1:4000 in Casein Assay Buffer, was added to the wells for 1 hr at RT. The colorimetric substrate, Slow TMB-ELISA (Pierce), was added and allowed to react for 15 minutes at RT, after which the enzymatic reaction was stopped by the addition of 25 μ l 2 N H₂SO₄. The reaction product was quantified using a Molecular Devices Vmax measuring the difference in absorbance at 450 nm and 650 nm.

6. Measurement of APP Levels

[0189] Two different APP assays were utilized. The first, designated APP- α /FL, recognizes both APP-alpha (α) and full-length (FL) forms of APP. The second assay is specific for APP- α . The APP- α /FL assay recognizes secreted APP including the first 12 amino acids of A β . Since the reporter antibody (2H3) is not specific to the α -clip-site, occurring between amino acids 612-613 of APP695 (Esch et al., Science 248, 1122-1124 (1990)); this assay also recognizes full length APP (APP-FL). Preliminary experiments using immobilized APP antibodies to the cytoplasmic tail of APP-FL to deplete brain homogenates of APP-FL suggest that approximately 30-40% of the APP- α /FL APP is FL (data not shown). The capture antibody for both the APP- α /FL and APP- α assays is mAb 8E5, raised against amino acids 444 to 592 of the APP695 form (Games et al., supra). The reporter mAb for the APP- α /FL assay is mAb 2H3, specific for amino acids 597-608 of APP695 (Johnson-Wood et al., supra) and the reporter antibody for the APP- α assay is a biotinylated derivative of mAb 16H9, raised to amino acids 605 to 611 of APP. The lower limit of sensitivity of the APP- α /FL assay is about 11 ng/ml (150 pM) (Johnson-Wood et al.) and that of the APP- α specific assay is 22 ng/ml (0.3 nM). For both APP assays, mAb 8E5 was coated onto the wells of 96-well EIA plates as described above for mAb 266. Purified, recombinant secreted APP- α was used as the reference standard for the APP- α assay and the APP- α /FL assay (Esch et al., supra). The brain homogenate samples in 5 M guanidine were diluted 1:10 in ELISA Specimen Diluent (0.014 M phosphate buffer, pH 7.4, 0.6% bovine serum albumin, 0.05% thimerosal, 0.5 M NaCl, 0.1% NP40). They were then diluted 1:4 in Specimen Diluent containing 0.5 M guanidine. Diluted homogenates were then centrifuged at 16,000 x g for 15 seconds at RT. The APP standards and samples were added to the plate in duplicate aliquots and incubated for 1.5 hr at RT. The biotinylated reporter antibody 2H3 or 16H9 was incubated with samples for 1 hr at RT. Streptavidin-alkaline phosphatase (Boehringer Mannheim), diluted 1:1000 in specimen diluent, was incubated in the wells for 1 hr at RT. The fluorescent substrate 4-methyl-umbelliphenyl-phosphate was added for a 30-min RT incubation and the plates were read on a Cytofluor tm 2350 fluorimeter (Millipore) at 365 nm excitation and 450 nm emission.

7. Immunohistochemistry

[0190] Brains were fixed for three days at 4° C in 4% paraformaldehyde in PBS and then stored from one to seven days at 4° C in 1% paraformaldehyde, PBS until sectioned. Forty-micron-thick coronal sections were cut on a vibratome at RT and stored in cryoprotectant (30% glycerol, 30% ethylene glycol in phosphate buffer) at -20° C prior to immunohistochemical processing. For each brain, six sections at the level of the dorsal hippocampus, each separated by consecutive 240 μ m intervals, were incubated overnight with one of the following antibodies: (1) a biotinylated anti-A β (mAb, 3D6, specific for human A β) diluted to a concentration of 2 μ g/ml in PBS and 1% horse serum; or (2) a biotinylated mAb specific for human APP, 8E5, diluted to a concentration of 3 μ g/ml in PBS and 1.0% horse serum; or (3) a mAb specific for glial fibrillary acidic protein (GFAP; Sigma Chemical Co.) diluted 1:500 with 0.25% Triton X-100 and 1% horse serum, in Tris-buffered saline, pH 7.4 (TBS) ; or (4) a mAb specific for CD11b, MAC-1 antigen, (Chemicon International) diluted 1:100 with 0.25% Triton X-100 and 1% rabbit serum in TBS; or (5) a mAb specific for MHC II antigen, (Pharmingen) diluted 1:100 with 0.25% Triton X-100 and 1% rabbit serum in TBS; or (6) a rat mAb specific for CD 43 (Pharmingen) diluted 1:100 with 1% rabbit serum in PBS or (7) a rat mAb specific for CD 45RA (Pharmingen) diluted 1:100 with 1% rabbit serum in PBS; or (8) a rat monoclonal A β specific for CD 45RB (Pharmingen) diluted 1:100 with 1% rabbit serum in PBS; or (9) a rat monoclonal A β specific for CD 45 (Pharmingen) diluted 1:100 with 1% rabbit serum in PBS; or (10) a biotinylated polyclonal hamster A β specific for CD3e (Pharmingen) diluted 1:100 with 1% rabbit serum in PBS or (11) a rat mAb specific for CD3 (Serotec) diluted 1:200 with 1% rabbit serum in PBS; or with (12) a solution of PBS lacking a primary antibody containing 1% normal horse serum.

[0191] Sections reacted with antibody solutions listed in 1,2 and 6-12 above were pretreated with 1.0% Triton X-100, 0.4% hydrogen peroxide in PBS for 20 min at RT to block endogenous peroxidase. They were next incubated overnight at 4° C with primary antibody. Sections reacted with 3D6 or 8E5 or CD3e mAbs were then reacted for one hr at RT with a horseradish peroxidase-avidin-biotin-complex with kit components "A" and "B" diluted 1:75 in PBS (Vector Elite Standard Kit, Vector Labs, Burlingame, CA.). Sections reacted with antibodies specific for CD 45RA, CD 45RB, CD 45, CD3 and the PBS solution devoid of primary antibody were incubated for 1 hour at RT with biotinylated anti-rat IgG (Vector) diluted

1:75 in PBS or biotinylated anti-mouse IgG (Vector) diluted 1:75 in PBS, respectively. Sections were then reacted for one hr at RT with a horseradish peroxidase-avidin-biotin-complex with kit components "A" and "B" diluted 1:75 in PBS (Vector Elite Standard Kit, Vector Labs, Burlingame, CA.).

[0192] Sections were developed in 0.01% hydrogen peroxide, 0.05% 3,3'-diaminobenzidine (DAB) at RT. Sections destined for incubation with the GFAP-, MAC-1- AND MHC II-specific antibodies were pretreated with 0.6% hydrogen peroxide at RT to block endogenous peroxidase then incubated overnight with the primary antibody at 4 °C. Sections reacted with the GFAP antibody were incubated for 1 hr at RT with biotinylated anti-mouse IgG made in horse (Vector Laboratories; Vectastain Elite ABC Kit) diluted 1:200 with TBS. The sections were next reacted for one hr with an avidin-biotin-peroxidase complex (Vector Laboratories; Vectastain Elite ABC Kit) diluted 1:1000 with TBS. Sections incubated with the MAC-1-or MHC II-specific mAb as the primary antibody were subsequently reacted for 1 hr at RT with biotinylated anti-rat IgG made in rabbit diluted 1:200 with TBS, followed by incubation for one hr with avidin-biotin-peroxidase complex diluted 1:1000 with TBS. Sections incubated with GFAP-, MAC-1- and MHC II-specific antibodies were then visualized by treatment at RT with 0.05% DAB, 0.01% hydrogen peroxide, 0.04% nickel chloride, TBS for 4 and 11 min, respectively.

[0193] Immunolabeled sections were mounted on glass slides (VWR, Superfrost slides), air dried overnight, dipped in Propar (Anatech) and overlaid with coverslips using Permount (Fisher) as the mounting medium.

[0194] To counterstain A β plaques, a subset of the GFAP-positive sections were mounted on Superfrost slides and incubated in aqueous 1% Thioflavin S (Sigma) for 7 min following immunohistochemical processing. Sections were then dehydrated and cleared in Propar, then overlaid with coverslips mounted with Permount.

8. Image Analysis

[0195] A Videometric 150 Image Analysis System (Oncor, Inc., Gaithersburg, MD) linked to a Nikon Microphot-FX microscope through a CCD video camera and a Sony Trinitron monitor was used for quantification of the immunoreactive slides. The image of the section was stored in a video buffer and a color-and saturation-based threshold was determined to select and calculate the total pixel area occupied by the immunolabeled structures. For each section, the hippocampus was manually outlined and the total pixel area occupied by the hippocampus was calculated. The percent amyloid burden was measured as: (the fraction of the hippocampal area containing A β deposits immunoreactive with mAb 3D6) x 100. Similarly, the percent neuritic burden was measured as: (the fraction of the hippocampal area containing dystrophic neurites reactive with mAb 8E5) x100. The C-Imaging System (Compix, Inc., Cranberry Township, PA) operating the Simple 32 Software Application program was linked to a Nikon Microphot-FX microscope through an Optronics camera and used to quantitate the percentage of the retrosplenial cortex occupied by GFAP-positive astrocytes and MAC-1-and MHC II-positive microglia. The image of the immunoreacted section was stored in a video buffer and a monochrome-based threshold was determined to select and calculate the total pixel area occupied by immunolabeled cells. For each section, the retrosplenial cortex (RSC) was manually outlined and the total pixel area occupied by the RSC was calculated. The percent astrocytosis was defined as: (the fraction of RSC occupied by GFAP-reactive astrocytes) X 100. Similarly, percent microgliosis was defined as: (the fraction of the RSC occupied by MAC-1- or MHC II-reactive microglia) X 100. For all image analyses, six sections at the level of the dorsal hippocampus, each separated by consecutive 240 μ m intervals, were quantitated for each animal. In all cases, the treatment status of the animals was unknown to the observer.

[0196] Although the foregoing invention has been described in detail for purposes of clarity of understanding, it will be obvious that certain modifications may be practiced.

TABLE 1									
TITER AT 50% MAXIMAL O.D.									
Aggregated A β Injected mice									
Age of PDAPP	mouse 100	mouse 101	mouse 102	mouse 103	mouse 104	mouse 105	mouse 106	mouse 107	mouse 108
4	70000	150000	15000	120000	1000	15000	50000	80000	100000
6	15000	65000	30000	55000	300	15000	15000	50000	60000

EP 1 690 547 B1

(continued)

5					TABLE 1					
				TITER AT 50% MAXIMAL O.D.						
10										
				Aggreated Aβ Injected mice						
15	Age ol PDAPP	mouse 100	mouse 101	mouse 102	mouse 103	mouse 104	mouse 105	mouse 106	mouse 107	mouse 108
	8	20000	55000	50000	50000	400	15000	18000	50000	60000
	10	40000	20000	60000	50000	900	15000	50000	20000	40000
	12	25000	30000	60000	40000	2700	20000	70000	25000	20000
20										
25										
30										
35			PBS injected mice on both Immunogens							
				al 1/100						
			Age ol PDAPP	mouse 113	mouse 114	mouse 115	mouse 116	mouse 117		
40										
			6	< 4x bk	< 4x bkg	< 4x bkg	< 4x bkg	< 4x bkg		
			10	5 x bkg	< 4x bkg	< 4x bkg	< 4x bkg	< 4x bkg		
			12	< 4x bkg	< 4x bkg	< 4x bkg	< 4x bkg	< 4x bkg		
45										

Claims

1. A pharmaceutical composition for use in treatment or prevention of disease comprising an immunogenic agent effective to induce an immunogenic response against A β in a patient, and a pharmaceutically acceptable adjuvant, wherein the agent is A β or an immunogenic fragment of A β .
2. An immunogenic agent, wherein the agent is A β or an immunogenic fragment of A β , for preventing or treating a disease associated with amyloid deposits of A β in the brain of a patient, wherein the agent is adapted for the further administration of an adjuvant that enhances immune response to the A β peptide, wherein the adjuvant and the agent are optionally administered together in the form of a composition.
3. Use of an immunogenic agent, wherein the agent is A β or an immunogenic fragment of A β , in the manufacture of

a medicament for preventing or treating a disease associated with amyloid deposits of A β in the brain of a patient, wherein the medicament is adapted for the further administration of an adjuvant that enhances immune response to the A β peptide; optionally the medicament being in the form of a composition wherein the adjuvant and the agent may be administered together.

4. A pharmaceutical composition of claim 1, an agent of claim 2 or use of claim 3, wherein said prevention or treatment is monitored by assaying antibody responses to the immunogenic agent over time.
5. An agent of claim 2 or use of claim 3, wherein the adjuvant is administered before or after the agent.
6. The pharmaceutical composition, agent or use of any preceding claim, wherein A β is
 - i. A β 43;
 - ii. A β 42;
 - iii. A β 41;
 - iv. A β 40; or
 - v. A β 39.
7. The pharmaceutical composition, agent or use of any preceding claim, wherein the immunogenic A β fragment is from the N-terminal half of A β .
8. The pharmaceutical composition, agent or use of claim 7, wherein the immunogenic A β fragment is A β 1-5 or A β 1-6.
9. The pharmaceutical composition, agent or use of any preceding claim, wherein the immunogenic agent includes multimers of the monomeric immunogenic agent recited in any of claims 6-8.
10. The pharmaceutical composition, agent or use of any preceding claim, comprising a dose of greater than 10 μ g of the immunogenic agent.
11. The pharmaceutical composition, agent or use of any one of claims 1-10, wherein the adjuvant comprises alum.
12. The pharmaceutical composition, agent or use of any one of claims 1-10, wherein the adjuvant comprises 3 De-O-acylated monophosphoryl lipid A (MPLTM).
13. The pharmaceutical composition, agent or use of any one of claims 1-10, wherein the adjuvant comprises StimulonTM QS-21.
14. The pharmaceutical composition, agent or use of any one of the preceding claims, wherein the agent is a component of a particle.
15. The pharmaceutical composition, agent or use of claim 14, wherein the particle is a liposome or a micro particle and the agent is emulsified or encapsulated in the liposome or micro particle.
16. The pharmaceutical composition, agent or use of claim 14 or claim 15, wherein the particle or micro particle is a polylactide polyglycolide copolymer (PLPG) particle or micro particle.
17. The pharmaceutical composition, agent or use of any preceding claim, wherein the disease is Alzheimer's disease.
18. The pharmaceutical composition, agent or use of any preceding claim, wherein the patient is:
 - a. asymptomatic; and/or
 - b. under 50; and/or
 - i. has inherited risk factors indicating susceptibility to Alzheimer's disease; or
 - ii. has no known risk factors for Alzheimer's disease.

Patentansprüche

- 5 1. Pharmazeutische Zusammensetzung zur Verwendung bei der Behandlung oder Verhinderung einer Erkrankung, wobei die pharmazeutische Zusammensetzung ein immunogenes Agens, die dahingehend wirksam ist, eine immunogene Antwort gegen A β in einem Patienten zu induzieren, und ein pharmazeutisch unbedenkliches Adjuvans umfasst, wobei es sich bei dem Agens um A β oder ein immunogenes Fragment von A β handelt.
- 10 2. Immunogenes Agens, wobei es sich bei dem Agens um A β oder ein immunogenes Fragment von A β handelt, zum Verhindern oder Behandeln einer Erkrankung, die mit Amyloidablagerungen von A β im Gehirn eines Patienten assoziiert wird, wobei das Agens zur weiteren Verabreichung eines Adjuvans geeignet ist, das eine Immunantwort auf das A β -Peptid verstärkt, wobei das Adjuvans und das Agens gegebenenfalls zusammen in der Form einer Zusammensetzung verabreicht werden.
- 15 3. Verwendung eines immunogenen Agens, wobei es sich bei dem Agens um A β oder ein immunogenes Fragment von A β handelt, bei der Herstellung eines Arzneimittels zum Verhindern oder Behandeln einer Erkrankung, die mit Amyloidablagerungen von A β im Gehirn eines Patienten assoziiert wird, wobei das Arzneimittel zur weiteren Verabreichung eines Adjuvans geeignet ist, das eine Immunantwort auf das A β -Peptid verstärkt; wobei das Arzneimittel gegebenenfalls in der Form einer Zusammensetzung ist, wobei das Adjuvans und das Agens zusammen verabreicht werden können.
- 20 4. Pharmazeutische Zusammensetzung nach Anspruch 1, Agens nach Anspruch 2 oder Verwendung nach Anspruch 3, wobei die Verhinderung oder Behandlung überwacht wird, indem die Antikörper-Antworten auf das immunogene Agens im Zeitablauf geprüft werden.
- 25 5. Agens nach Anspruch 2 oder Verwendung nach Anspruch 3, wobei das Adjuvans vor oder nach dem Agens verabreicht wird.
- 30 6. Pharmazeutische Zusammensetzung, Agens oder Verwendung nach einem der vorhergehenden Ansprüche, wobei es sich bei A β um
 - i. A β 43;
 - ii. A β 42;
 - iii. A β 41;
 - iv. A β 40 oder
 - 35 v. A β 39 handelt.
7. Pharmazeutische Zusammensetzung, Agens oder Verwendung nach einem der vorhergehenden Ansprüche, wobei das immunogene A β -Fragment von der N-terminalen Hälfte von A β ist.
- 40 8. Pharmazeutische Zusammensetzung, Agens oder Verwendung nach Anspruch 7, wobei es sich bei dem immunogenen A β -Fragment um A β 1-5 oder A β 1-6 handelt.
9. Pharmazeutische Zusammensetzung, Agens oder Verwendung nach einem der vorhergehenden Ansprüche, wobei das immunogene Agens Multimere des in einem der Ansprüche 6 - 8 aufgeführten monomeren immunogenen Agens enthält.
- 45 10. Pharmazeutische Zusammensetzung, Agens oder Verwendung nach einem der vorhergehenden Ansprüche, die bzw. das eine Dosis des immunogenen Agens von mehr als 10 μ g umfasst.
- 50 11. Pharmazeutische Zusammensetzung, Agens oder Verwendung nach einem der Ansprüche 1 - 10, wobei das Adjuvans Alaun umfasst.
12. Pharmazeutische Zusammensetzung, Agens oder Verwendung nach einem der Ansprüche 1 - 10, wobei das Adjuvans 3-Des-O-acyliertes Monophosphoryl-Lipid A (MPLTM) umfasst.
- 55 13. Pharmazeutische Zusammensetzung, Agens oder Verwendung nach einem der Ansprüche 1 - 10, wobei das Adjuvans StimulonTM QS-21 umfasst.

14. Pharmazeutische Zusammensetzung, Agens oder Verwendung nach einem der vorhergehenden Ansprüche, wobei es sich bei dem Agens um einen Bestandteil eines Teilchens handelt.

15. Pharmazeutische Zusammensetzung, Agens oder Verwendung nach Anspruch 14, wobei es sich bei dem Teilchen um ein Liposom oder ein Mikroteilchen handelt und das Agens in das Liposom oder Mikroteilchen emulgiert oder in dem Liposom oder Mikroteilchen eingekapselt wird.

16. Pharmazeutische Zusammensetzung, Agens oder Verwendung nach Anspruch 14 oder 15, wobei es sich bei dem Teilchen oder Mikroteilchen um ein Teilchen oder Mikroteilchen eines Polylactid/Polyglykolid-Copolymers (PLPG) handelt.

17. Pharmazeutische Zusammensetzung, Agens oder Verwendung nach einem der vorhergehenden Ansprüche, wobei es sich bei der Erkrankung um Alzheimer-Krankheit handelt.

18. Pharmazeutische Zusammensetzung, Agens oder Verwendung nach einem der vorhergehenden Ansprüche, wobei der Patient Folgendes ist:

- a. asymptomatisch und/oder
- b. jünger als 50 Jahre und/oder

- i. vererbte Risikofaktoren aufweist, die auf eine Empfänglichkeit für Alzheimer-Krankheit hindeuten; oder
- ii. keine bekannten Risikofaktoren für Alzheimer-Krankheit aufweist.

Revendications

1. Composition pharmaceutique à utiliser dans le traitement ou dans la prévention de maladies, comprenant un agent immunogène efficace pour induire une réponse immunogène dirigée contre A β dans un patient, et un adjuvant pharmaceutiquement acceptable, l'agent représentant A β ou un fragment immunogène de A β .

2. Agent immunogène, dans lequel l'agent représente A β ou un fragment immunogène de A β , pour la prévention ou le traitement d'une maladie associée à des dépôts amyloïdes de A β dans le cerveau d'un patient, l'agent étant conçu pour l'administration ultérieure d'un adjuvant qui amplifie la réponse immunitaire au peptide A β , l'adjuvant et l'agent étant administrés, de manière facultative, ensemble sous la forme d'une composition.

3. Utilisation d'un agent immunogène, dans laquelle l'agent représente A β ou un fragment immunogène de A β , dans la préparation d'un médicament destiné à la prévention ou au traitement d'une maladie associée à des dépôts amyloïdes de A β dans le cerveau d'un patient, le médicament étant conçu pour l'administration ultérieure d'un adjuvant qui amplifie la réponse immunitaire au peptide A β ; de manière facultative, le médicament se présentant sous la forme d'une composition dans laquelle l'adjuvant et l'agent peuvent être administrés de manière conjointe.

4. Composition pharmaceutique selon la revendication 1, agent selon la revendication 2 ou utilisation selon la revendication 3, dans lequel ladite prévention ou ledit traitement est surveillé via un dosage des réponses d'anticorps à l'agent immunogène au cours du temps.

5. Agent selon la revendication 2 ou utilisation selon la revendication 3, dans lequel l'adjuvant est administré avant ou après l'agent.

6. Composition pharmaceutique, agent ou utilisation selon l'une quelconque des revendications précédentes, dans lequel A β et :

- i. A β 43 ;
- ii. A β 42 ;
- iii. A β 41 ;
- iv. A β 40 ; ou
- v. A β 39.

7. Composition pharmaceutique, agent ou utilisation selon l'une quelconque des revendications précédentes, dans

lequel le fragment immunogène A β provient de la moitié de l'extrémité amino terminale de A β .

8. Composition pharmaceutique, agent ou utilisation selon la revendication 7, dans lequel le fragment immunogène A β est A β 1-5 ou A β 1-6.

9. Composition pharmaceutique, agent ou utilisation selon l'une quelconque des revendications précédentes, dans lequel l'agent immunogène englobe des multimères de l'agent immunogène monomère énoncé dans l'une quelconque des revendications 6 à 8.

10. Composition pharmaceutique, agent ou utilisation selon l'une quelconque des revendications précédentes, comprenant une dose supérieure à 10 μ g de l'agent immunogène.

11. Composition pharmaceutique, agent ou utilisation selon l'une quelconque des revendications 1 à 10, dans lequel l'adjuvant comprend de l'alun.

12. Composition pharmaceutique, agent ou utilisation selon l'une quelconque des revendications 1 à 10, dans lequel l'adjuvant comprend le monophosphoryl-lipide A 3-dé-O-acylé (MPLTM).

13. Composition pharmaceutique, agent ou utilisation selon l'une quelconque des revendications 1 à 10, dans lequel l'adjuvant comprend StimulonTM QS-21.

14. Composition pharmaceutique, agent ou utilisation selon l'une quelconque des revendications précédentes, dans lequel l'agent est un composant d'une particule.

15. Composition pharmaceutique, agent ou utilisation selon la revendication 14, dans lequel la particule est un liposome ou une microparticule et l'agent est émulsifié ou encapsulé dans le liposome ou dans la microparticule.

16. Composition pharmaceutique, agent ou utilisation selon la revendication 14 ou 15, dans lequel la particule ou la microparticule est une particule ou une microparticule d'un copolymère de polylactide-polyglycolide (PLPG).

17. Composition pharmaceutique, agent ou utilisation selon l'une quelconque des revendications précédentes, dans lequel la maladie est la maladie d'Alzheimer.

18. Composition pharmaceutique, agent ou utilisation selon l'une quelconque des revendications précédentes, dans lequel le patient est :

- (a) asymptomatique ; et/ou
- (b) âgé de moins de 50 ans ; et/ou

- (i) a hérité de facteurs de risque indiquant une sensibilité à la maladie d'Alzheimer ; ou
- (ii) ne présente aucun facteur de risque connu pour la maladie d'Alzheimer.

FIGURE 1


TITER OF AGGREGATED A β_{1-2} INJECTED PDAPP MICE OVER TIME

Figure 2

STUDY 001 HIPPOCAMPAL AMYLOID BURDEN




Figure 3

STUDY 001
HIPPOCAMPAL NEURITIC PLAQUE BURDEN




Figure 4

STUDY 001
RETROSPLLENAL CORTICAL ASTROCYTOSIS




Figure 5

Antibody Titer Response to Various Doses of AN1792 After 2, 3 and 4 Immunizations




Figure 6

Kinetics of Antibody Response to AN1792




Figure 7

STUDY 002
CORTICAL AMYLOID BURDEN




Figure 8

STUDY 002
CORTICAL NEURITIC PLAQUE BURDEN




Figure 9

STUDY 002
RETROSPLLENIAL CORTICAL ASTROCYTOSIS




Figure 10

Study 002: Splenocyte Proliferation Assay




Figure 11




Figure 12




Figure 13





Figure 14

Antibody Responses to AN1792 With Different Adjuvants



CORTEX

PBS CONTROL		UNTREATED CONTROL	
624-165	272	764-181	3470
625-166	1802	785-182	171
626-167	62	766-183	91
633-168	4696	767-184	6692
634-169	3090	768-185	1353
671-170	2417	771-186	1153
672-171	2840	772-187	3800
829-172	3320	780-188	3740
830-173	1833	843-189	163
831-174	416	844-190	122
792-175	126	845-191	427
793-176	2559	846-192	2674
794-177	289	887-193	453
732-178	179	888-194	2996
733-179	1329	889-195	1075
734-180	5665		
MEDIAN	1817	MEDIAN	1153
p VALUE (M-W)		p VALUE (M-W)	
MEAN	1931	MEAN	1825
ST. DEV.	1718	ST. DEV.	1769
% CV	89	% CV	97
p VALUE (t TEST)		p VALUE (t TEST)	
	n=16		n=15

FIG. 15A

CORTEX

2 mg ALUM 100 µg AN1528		50 µg MPL 100 µg AN1528	
660-083	295	643-105	385
661-084	3180	644-106	2640
662-085	2480	645-107	2403
633-086	3014	654-108	1741
664-087	5870	655-109	3053
665-088	5978	656-110	5990
693-089	1620	678-111	3360
694-090	35	679-112	1230
695-091	3400	704-114	2680
697-092	2630	705-115	78
698-093	983	706-116	1290
699-094	5327	729-117	3180
701-095	1862	730-118	1833
702-096	1849	731-119	4590
703-097	2239	736-120	1112
739-098	806	737-121	1653
740-099	5303	757-122	992
741-100	459	758-123	4692
800-103	154	808-124	785
801-104	852	809-125	244
		810-126	32
MEDIAN	2051	MEDIAN	1741
p VALUE (M-W)		p VALUE (M-W)	
MEAN	2407	MEAN	2140
ST. DEV.	1913	ST. DEV.	1659
% CV	79	% CV	78
p VALUE (t TEST)		p VALUE (t TEST)	
	n=20		n=21

FIG. 15B

CORTEX

25 µg QS21 100 µg AN1528		CFA/IFA 100 µg AN1792	
615-128	1257	539-068	693
616-129	361	640-069	508
617-130	1008	641-070	440
536-131	3290	642-071	467
637-132	2520	690-072	42
638-133	3880	691-073	2491
744-134	627	692-074	121
745-135	58	795-075	137
746-136	2610	796-076	822
747-137	1509	797-077	475
769-138	1788	748-087	600
770-139	988	749-079	78
773-140	1199	750-080	1267
774-141	339	751-081	1351
775-142	402	761-082	69
776-143	537		
840-144	1119		
841-145	194		
821-146	1259		
822-147	5413		
823-148	2233		
MEDIAN	1199	MEDIAN	475
p VALUE (M-W)		p VALUE (M-W)	0.0481
MEAN	1552	MEAN	637
ST. DEV.	1364	ST. DEV.	655
% CV	88	% CV	103
p VALUE (t TEST)		p VALUE (t TEST)	0.0106
n=21		n=15	

FIG. 15C

CORTEX

5 μ g THIMEROSAL/PBS 10 μ g AN1792		2 mg ALUM 100 μ g AN1792	
635-149	1337	610-001	432
669-150	4644	611-002	1012
670-151	6335	612-003	3607
673-152	3700	613-004	508
674-153	2750	620-005	465
676-154	1687	621-006	16
681-156	185	622-007	28
682-157	8031	623-008	217
683-158	3450	708-009	2738
754-159	157	709-010	927
755-160	6857	710-011	1609
756-161	482	716-012	1608
805-162	524	784-014	3890
806-163	397	785-015	1614
807-164	234	786-018	285
		787-017	3102
		788-018	1617
		789-019	1474
		815-020	424
		816-021	1375
		817-022	2323
MEDIAN	1687	MEDIAN	1375
p VALUE (M-W)		p VALUE (M-W)	0.5000
MEAN	2718	MEAN	1394
ST. DEV.	2685	ST. DEV.	1166
% CV	99	% CV	84
p VALUE (t TEST)		p VALUE (t TEST)	0.2650
	n=15		n=21

FIG. 15D

CORTEX

50 µg MPL 100 µg AN1792		25 µg QS21 100 µg AN1792	
646-023	2002	627-045	91
647-024	147	628-046	3397
648-025	1304	631-049	3702
649-026	34	632-050	1776
650-027	980	667-052	1832
724-028	1282	668-053	3023
726-030	1966	686-054	189
727-031	733	687-055	891
720-032	2563	688-056	240
721-033	5563	689-057	110
802-034	113	712-059	3311
803-035	671	825-061	1009
804-036	51	826-082	18165
811-037	613	827-063	73
812-038	332	828-064	78
813-039	1454	837-065	1051
814-040	2441	838-066	270
833-014	742	839-067	371
834-042	40		
836-044	807		
MEDIAN	774	MEDIAN	950
p VALUE (M-W)	0.1710	p VALUE (M-W)	0.4076
MEAN	1192	MEAN	2199
ST. DEV.	1299	ST. DEV.	4187
% CV	109	% CV	190
p VALUE (t TEST)	0.1506	p VALUE (t TEST)	0.8131
n=21		n=18	

FIG. 15E

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 9213069 A, Hardy [0002]
- EP 526511 A [0004] [0004] [0004]
- US 4666829 A [0039]
- WO 9512608 A [0046]
- WO 9306121 A [0046]
- WO 9408051 A [0046]
- WO 9535503 A [0046]
- WO 9530642 A [0046]
- WO 9118980 A, Devlin [0046]
- US 5612486 A, McConlogue [0047]
- WO 9717613 A [0049]
- WO 9717614 A [0049]
- WO 9412629 A, Woo [0053]
- US 5208036 A [0054]
- US 5264618 A [0054]
- US 5279833 A [0054]
- US 5283185 A [0054]
- US 5399346 A [0055]
- WO 9505853 A [0055]
- GB 2220211 A [0063]
- US 5057540 A [0063]
- WO 9014837 A [0064]

Non-patent literature cited in the description

- Selkoe. *TINS*, 1993, vol. 16, 403-409 [0002]
- Selkoe. *J. Neuropathol. Exp. Neurol.*, 1994, vol. 53, 438-447 [0002]
- Duff et al. *Nature*, 1995, vol. 373, 476-477 [0002]
- Games et al. *Nature*, 1995, vol. 373, 523 [0002]
- Goate et al. *Nature*, 1991, vol. 349, 704 [0003]
- Chartier Harlan et al. *Nature*, 1991, vol. 353, 844 [0003]
- Murrell et al. *Science*, 1991, vol. 254, 97 [0003]
- Mullan et al. *Nature Genet.*, 1992, vol. 1, 345 [0003]
- Hardy. *TINS*, 1997, vol. 20, 154 [0003] [0039]
- Seubert et al. *Nature*, 1992, vol. 359, 325-327 [0004]
- Gupta. *Vaccine*, 1997, vol. 15, 1341-3 [0011]
- Smith ; Waterman. *Adv. Appl. Math.*, 1981, vol. 2, 482 [0022]
- Needleman ; Wunsch. *J. Mol. Biol.*, 1970, vol. 48, 443 [0022]
- Pearson ; Lipman. *Proc. Nat'l. Acad. Sci. USA*, 1988, vol. 85, 2444 [0022]
- Altschul et al. *J. Mol. Biol.*, 1990, vol. 215, 403-410 [0022]
- Henikoff ; Henikoff. *Proc. Natl. Acad. Sci. USA*, 1989, vol. 89, 10915 [0022]
- Kang et al. *Nature*, 1987, vol. 325, 773 [0027]
- Ponte et al. *Nature*, 1988, vol. 331, 525 [0027]
- Kitaguchi et al. *Nature*, 1988, vol. 331, 530 [0027]
- Epitope Mapping Protocols in Methods in Molecular Biology. 1996, vol. 66 [0028]
- Burke et al. *J. Inf. Dis.*, 1994, vol. 170, 1110-19 [0028]
- Tigges et al. *J. Immunol.*, vol. 156, 3901-3910 [0028]
- Weissmann et al. *Curr. Opin. Neurobiol.*, 1997, vol. 7, 695-700 [0037]
- Smits et al. *Veterinary Quarterly*, 1997, vol. 19, 101-105 [0037]
- Nathanson et al. *Am. J. Epidemiol.*, 1997, vol. 145, 959-969 [0037]
- Glenner ; Wong. *Biochem. Biophys. Res. Commun.*, 1984, vol. 120, 1131 [0039]
- Hardy et al. *TINS*, 1997, vol. 20, 155-158 [0041]
- Sambrook et al. *Molecular Cloning: A Laboratory Manual*. C.S.H.P. Press, 1989 [0043]
- Hsiao et al. *Science*, 1999, vol. 274, 99 [0047]
- Staufenbiel et al. *Proc. Natl. Acad. Sci. USA*, 1997, vol. 94, 13287-13292 [0047]
- Sturchler-Pierrat et al. *Proc. Natl. Acad. Sci. USA*, 1997, vol. 94, 13287-13292 [0047]
- Borchelt et al. *Neuron*, 1997, vol. 19, 939-945 [0047]
- *Immun. Rev.*, 1982, vol. 62, 185 [0050]
- Lawrie ; Tumin. *Cur. Opin. Genet. Develop.*, 1993, vol. 3, 102-109 [0053]
- Bett et al. *J. Virol.*, 1993, vol. 67, 5911 [0053]
- Zhou et al. *J. Exp. Med.*, 1994, vol. 179, 1867 [0053]
- Dubensky et al. *J. Virol.*, 1996, vol. 70, 508-519 [0053]
- Ohe et al. *Human Gene Therapy*, 1995, vol. 6, 325-333 [0053]
- Xiao ; Brandsma. *Nucleic Acids. Res.*, 1996, vol. 24, 2630-2622 [0053]
- McGee et al. *J. Micro Encap.*, 1996 [0054]
- Kensil et al. *Vaccine Design: The Subunit and Adjuvant Approach*. Plenum Press, 1995 [0063]
- Stoute et al. *N. Engl. J. Med.*, 1997, vol. 336, 86-91 [0063]
- *Bioworld Today*, 15 November 1998 [0063]

EP 1 690 547 B1

- **Livingston.** *J. Immunol.*, 1997, vol. 159, 1383-1392 [0063]
- **Chang et al.** *Advanced Drug Delivery Reviews*, 1998, vol. 32, 173-186 [0065]
- Remington's Pharmaceutical Science. Mack Publishing Company, 1980 [0066]
- **Langer.** *Science*, 1990, vol. 249, 1527 [0069]
- **Hanes.** *Advanced Drug Delivery Reviews*, 1997, vol. 28, 97-119 [0069]
- **Glenn et al.** *Nature*, 1998, vol. 391, 851 [0072]
- **Paul et al.** *Eur. J. Immunol.*, 1995, vol. 25, 3521-24 [0073]
- **Cevc et al.** *Biochem. Biophys. Acta*, 1998, vol. 1368, 201-15 [0073]
- **Johnson-Wood et al.** *Proc. Natl. Acad. Sci. USA*, 1997, vol. 94, 1550-1555 [0102]
- **Oltersdorf et al.** *J. Biol. Chem.*, 1990, vol. 265, 4492-4497 [0130]
- **Esch et al.** *Science*, 1990, vol. 248, 1122-1124 [0189]